

CURRICULUM VITAE
Frederick G. Hayden, M.D., F.A.C.P.

Address: University of Virginia Health System
Box 800473 Dept. of Internal Medicine
Hospital Drive, Private Clinics, Rm 6557
Charlottesville, Virginia 22908

University of Virginia Respiratory Disease Study Unit
400 Brandon Ave – G020
P. O. Box 800760
Charlottesville, VA 22908

Personal: Born 11 January, 1948, Madison, Wisconsin

Education: 1966-68 University of Wisconsin, Madison Wisconsin
1968-69 Albert Ludwigs University, Freiburg, Germany
1971 B.A., Stanford University, Stanford, California
1969-73 M.D., Stanford University School of Medicine, Stanford, California

Postdoctoral Training: 1973-74 Intern in Medicine, Strong Memorial Hospital,
Rochester, New York, (Dr. Lawrence E. Young)
1974-76 Resident in Medicine, Strong Memorial Hospital,
Rochester, New York (Dr. Daniel Kimburg and Dr. William Morgan)
1976-78 Trainee and Fellow in Infectious Diseases, University of Rochester School
of Medicine, Rochester, New York (Dr. R. Gordon Douglas, Jr. and Dr.
William Morgan)

Postdoctoral Certification: 1974 National Board of Medical Examiners
1976 American Board of Internal Medicine
1982 Subspecialty Board in Infectious Diseases

Licensure: 1978- Virginia

Academic Appointments: 1978-84 Assistant Professor of Internal Medicine and Pathology,
University of Virginia School of Medicine, Charlottesville, Virginia
1984-90 Associate Professor of Internal Medicine and
Pathology, University of Virginia School of Medicine
1986-90 Chairholder, Stuart S. Richardson Professorship of Clinical
Virology in Internal Medicine, University of Virginia School of Med.
1988-89 Attached Worker, Division of Virology, National Institute for Medical
Research, London, England (Dr. Alan J. Hay and Dr. John J. Skehel)
1990- Stuart S. Richardson Professor of Clinical Virology in Internal Medicine
and Professor of Internal Medicine and Pathology,
University of Virginia School of Medicine, Charlottesville, Virginia

Administrative Appointments: 1978-2001 Associate Director, Clinical Microbiology Laboratory (Virology),
University of Virginia Health Sciences Center
Associate Director, Respiratory Disease Study Unit, The Center for The
Prevention of Disease and Injury, University of Virginia
1986-

Committees:	1984-88	Member, Human Investigation Committee, University of Virginia Medical Center
	1988-	Member, HIV and AIDS Advisory Committee, University of Virginia Health Sciences Center
	1988-	Member, Infection Control Committee, University of Virginia Health Sciences Center
	1994-	Member, Promotions Committee, Department of Internal Medicine
	1998-	Member, Pharmacy and Therapeutics Antimicrobial Subcommittee, University of Virginia Health Sciences Center
Editorial Boards:	1985-90	Antimicrobial Agents and Chemotherapy
	1990-95	Editor, Antimicrobial Agents and Chemotherapy
	1985-	Antiviral Research
	1989-00	Antiviral Chemistry and Chemotherapy
	1992-01	International Antiviral News
	1995-	Antiviral Therapy
	1999-	International Journal of Antimicrobial Agents
	2001-	Journal of Antimicrobial Chemotherapy
Other:	1978-86	USA-USSR Joint Scientific Exchange Program
	1994-99	Program Committee, Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology
	1995-98	Executive Committee, International Society of Chemotherapy
	1995-	Executive Committee, NIAID Collaborative Antiviral Study Group
	1996-	Board of Directors, International Society for Antiviral Research
	1999-2000	Co-Chair, Harold C. Neu Infectious Diseases Conference
1998-	Co-Chair, I-IV International Symposia on Influenza and Other Respiratory Viruses	
Honors:	1969	Phi Beta Kappa, University of Wisconsin
	1973	Alpha Omega Alpha, Stanford University
	1996	James H. Nakano Citation, Centers for Disease Control and Prevention
	2001	Clinical Virology Award, Pan American Society for Clinical Virology
Professional Societies:		American Academy of Microbiology (Fellow, 1994)
		American College of Physicians (Fellow, 1982)
		American Federation for Clinical Research
		American Society for Clinical Investigation (1992)
		American Society for Microbiology
		American Society for Virology
		American Association for the Advancement of Sciences
		Infectious Diseases Society of America (Fellow, 1986)
		International Society for Antiviral Research
	Pan American Group for Rapid Viral Diagnosis	
	Southern Society for Clinical Investigation (1986)	

Bibliography

Original Articles

1. Hayden FG, WJ Hall, RG Douglas Jr, and DM Speers. Amantadine aerosols in normal volunteers; pharmacology and safety testing. *Antimicrob Agents Chemother* 16:644-650, 1979.
2. Douglas RG Jr, LJ Markoff, BR Chanock, RF Betts, FG Hayden, MM Levine, GA Van Blerk, SB Scotman, and DR Nalin. Live Victoria/75-ts-1 [E] influenza A virus vaccines in adult volunteers: Role of hemagglutinin immunity in protection against illness and infection caused by influenza A virus. *Infect Immun* 26:275-279, 1979.
3. Hayden FG, WJ Hall, and RG Douglas Jr. Therapeutic effect of aerosolized amantadine HCl in naturally acquired influenza A virus infection. *J Infect Dis* 141:535-542, 1980.
4. Hayden FG, MK Cote, and RG Douglas Jr. Plaque inhibition assay for susceptibility testing of influenza viruses. *Antimicrob Agents Chemother* 17:865-870, 1980.
5. Hayden FG, RG Douglas Jr, and R Simons. Enhancement of activity against influenza viruses by combination of antivirals. *Antimicrob Agents Chemother* 18:536-541, 1980.
6. VanVorhis LP, RB Betts, FG Hayden, WA Christmas, and RG Douglas Jr. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. *J Amer Med Assoc* 245:1128-1131, 1981.
7. Hayden FG, B Giordani, JM Gwaltney Jr, RL Van de Castle, and KF Adams. Comparative toxicity of amantadine HCl and rimantadine HCl in healthy adults. *Antimicrob Agents Chemother* 19:226-233, 1981.
8. Gigliotti F, WT Williams, FG Hayden, and JO Hendley. Etiology of acute conjunctivitis in children. *J Pediatr* 98:531-536, 1981.
9. Whitley RJ, SJ Soong, MS Hirsch, AW Karchmer, R. Dolin, G Galasso, JK Dunnick, CA Alford Jr, and the NIAID Collaborative Antiviral Study Group [FG Hayden]. Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. *N Engl J Med* 304:313-318, 1981.
10. Whitley, RJ, J Tilles, C Linneman, C Liu, G Pazin, M Hilty, J Overall, AM Visintine, SJ Soong, CA Alford Jr, and the NIAID Collaborative Antiviral Study Group [FG Hayden]. Herpes simplex encephalitis: clinical assessment. *J Amer Med Assoc* 247:317-318, 1981.
11. Hayden FG and JM Gwaltney. Prophylactic activity of intranasal enviroxime experimentally induced rhinovirus type 39 infection. *Antimicrob Agents Chemother* 21:892-897, 1982.
12. Hayden FG, DM Zyldikov, VI Iljenko, and YV Padolka. Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection. *Antiviral Res* 2:147-153, 1982.
13. Powers RD, JM Gwaltney Jr, and FG Hayden. Activity of MDL-860 [2-(3,4, dichlorophenoxy)-4-nitrobenzotrile] against picornaviruses . *Antimicrob Agents Chemother* 22:639-642, 1982.
14. Whitley RJ, SJ Soong, R Dolin, R Betts, C Linneman, CA Alford Jr, and the NIAID Collaborative Antiviral Study Group [FG Hayden]. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. *N Engl J Med* 307:971-975, 1982.
15. Nahmias AJ, RJ Whitley, AN Visintine, Y Takei, CA Alford Jr, and the NIAID Collaborative Antiviral Study Group [FG Hayden]. Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance. *J Infect Dis* 145:829-836, 1982.
16. Powers RD, MF Rein, and FG Hayden. Necrotizing balanitis due to herpes simplex type 1. *J Amer Med Assoc* 248:215-216, 1982.

Bibliography

17. Hayden FG, HE Hoffman, and DA Spyker. Differences in amantadine HCl and rimantadine HCl toxicities relate to differences in pharmacokinetics. *Antimicrob Agents Chemother* 23:458-464, 1983.
18. Turner RB, FG Hayden, and JO Hendley. Counterimmunoelectrophoresis of urine for diagnosis of bacterial pneumonia in pediatric outpatients. *Pediatr* 71:788-790, 1983.
19. Hayden FG and JM Gwaltney Jr. Antiinterferon antibody increases rhinovirus isolation rates from nasal wash samples containing interferon. *Antiviral Res* 3:67-71, 1983.
20. Hayden FG, AS Sorensen, and JA Bateman. Comparison of the Immulok Cultureset kit and virus isolation for detection of herpes simplex virus in clinical specimens. *J Clin Microbiol* 18:222-224, 1983.
21. Powers RD, WM Dotson Jr, and FG Hayden. Modification of encephalomyocarditis virus-induced diabetes in mice by antiviral agents. *Antiviral Res* 3:151-159, 1983.
22. Hayden FG and JM Gwaltney Jr. Intranasal interferon- α_2 for the prevention of rhinovirus infection and illness. *J Infect Dis* 148:543-550, 1983.
23. Farr BM, JM Gwaltney Jr, FG Hayden, and GL Mandell. Human polymorphonuclear neutrophil functions are unaffected by recombinant DNA interferon. *Infect Immun* 42:1195-1197, 1983.
24. Hayden FG, SE Mills, and ME Johns. Human tolerance and histopathologic effects of chronic intranasal interferon- α_2 . *J Infect Dis* 148:914-921, 1983.
25. Helzlsouer KJ, FG Hayden, and AD Rogol. Severe metabolic complications in a cross country runner with sickle cell trait. *J Amer Med Assoc* 249:777-779, 1983.
26. Whitley RJ, S Spurance, FG Hayden, J Overall, CA Alford Jr, JM Gwaltney Jr, S-J Soong, and the NIAID Collaborative Antiviral Study Group. Vidarabine therapy of mucocutaneous herpes simplex virus infections in the immunocompromised host. *J Infect Dis* 149:1-8, 1984.
27. Hayden FG, AN Schleupushkin, and NL Pushkarskaya. Combined interferon- α_2 , rimantadine HCl, and ribavirin inhibition of influenza virus replication *in vitro*. *Antimicrob Agents Chemother* 25:53-57, 1984.
28. Powers RD, FG Hayden, J Samuelson, and JM Gwaltney Jr. Immune response of adults to sequential influenza vaccination. *J Med Virol* 14:169-175, 1984.
29. Farr BM, JM Gwaltney Jr, KF Adams, and FG Hayden. Intranasal interferon- α_2 for prevention of natural rhinovirus colds. *Antimicrob Agents Chemother* 26:31-34, 1984.
30. Hayden FG and JM Gwaltney Jr. Intranasal interferon- α_2 treatment of experimental rhinovirus colds. *J Infect Dis* 150:174-180, 1984.
31. Hayden FG, JM Gwaltney Jr, and ME Johns. Prophylactic efficacy and tolerance of low dose intranasal interferon- α_2 in natural respiratory viral infections. *Antiviral Res* 5:111-116, 1985.
32. Brandt SJ, CG Tribble, AD Lakeman, and FG Hayden. Herpes simplex burn wound infection: epidemiology of a case cluster and response to acyclovir therapy. *Surgery* 98:338-343, 1985.
33. Hayden FG, A Minocha, DA Spyker, and HE Hoffman. Comparative, single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. *Antimicrob Agents Chemother* 28:216-221, 1985.
34. Geist FC and FG Hayden. Comparative susceptibilities of strain MRC-5 human embryonic lung fibroblast

Bibliography

- cells and the Cooney strain of human fetal tonsil cells for isolation of rhinovirus from clinical specimens. *J Clin Microbiol* 22:455-456, 1985.
35. Quinn SF, S Erickson, D Oshman, and FG Hayden. Lobar collapse with respiratory syncytial virus pneumonitis. *Pediatr Radiol* 15:229-230, 1985.
 36. Hayden FG, J Albrecht, D Kaiser, and JM Gwaltney Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha₂-interferon. *N Engl J Med* 314:71-75, 1986.
 37. Whitley RJ, CA Alford, MS Hirsh, TR Schooley, JP Luby, FR Aoki, D Hanley, AJ Nahmias, S- J Soong, and the NIAID Collaborative Study Group [FG Hayden]. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. *N Engl J Med* 314:144-149, 1986.
 38. Hayden FG and AS Monto. Oral rimantadine hydrochloride therapy of H3N2 subtype influenza virus infection in adults. *Antimicrob Agents Chemother* 29:339-341, 1986.
 39. Wenzel RP, FG Hayden, DHM Groshell, RA Salata, WS Young, JE Greenlee, S Newman, PJ Miller, KE Hechemy, W Burgdorfer, MG Peacock, and LJ Rubinstein. Acute febrile cerebrovasculitis: a syndrome of unknown, perhaps Rickettsial, cause. *Ann Intern Med* 104:606-615, 1986.
 40. Gaffey MJ, JM Gwaltney Jr, WE Dressler, JV Sorrentino, and FG Hayden. Intranasal atropine methonitrate treatment of experimental rhinovirus colds. *Am Rev Resp Dis* 135:241-244, 1987.
 41. Winther B, DF Innes, SE Mills, N Mygind, D Zito, and FG Hayden. Lymphocyte subsets in normal airway mucosa of the human nose. *Arch Otolaryngology Head Neck Surg* 113:59-62, 1987.
 42. Hurley PT, RA Salata, and FG Hayden. Chronic gonococcal osteomyelitis. *South Med J* 80:264-266, 1987.
 43. Geist FC, Bateman JS, and FG Hayden. *In vitro* activity of zinc salts against human rhinoviruses. *Antimicrob Agents Chemother* 31:622-624, 1987.
 44. Hayden FG, B Winther, GR Donowitz, SE Mills, and DJ Innes. Human nasal mucosal responses to topically applied recombinant leukocyte A interferon. *J Infect Dis* 156:64-72, 1987.
 45. Stein DS, CM Creticos, GG Jackson, JM Bernstein, FG Hayden, GM Schiff and DI Bernstein. Oral ribavirin treatment of influenza A and B. *Antimicrob Agents Chemother* 31:1285-1287, 1987.
 46. Gaffey MJ, JM Gwaltney Jr, A Sastre, WE Dressler, JV Sorrentino, and FG Hayden. Intranasal and oral antihistamine treatment of experimental rhinovirus colds. *Amer Rev Resp Dis* 136:556-560, 1987.
 47. Mifflin TE, J Bowden, MA Lovell, DE Bruns, FG Hayden, DHM Groschell and J Savory. Comparison of radioactive (³²P and ³⁵S) and biotinylated probes for detection of cytomegalovirus DNA. *Clin Biochem* 20:231-235, 1987.
 48. Hayden FG, SE Mills, DJ Innes, A Darragh, M Just and SN Linder-Chiccolunghi. Tolerance and nasal histopathological effects of long-term, low-dose recombinant interferon alfa-2A (Roferon-A). *Antiviral Res* 8:139-149, 1987.
 49. VanLandingham KE, HB Barsteller, GW Ross and FG Hayden. Relapse of herpes simplex virus encephalitis after conventional acyclovir therapy. *J Amer Med Assoc* 259:1051-1053, 1988.
 50. Gaffey JM, DL Kaiser and FG Hayden. Ineffectiveness of oral terfenadine in natural colds: evidence against histamine as a mediator of common cold symptoms. *Pediatr Infect Dis* 7:215-242, 1988.

Bibliography

51. Stokes CE, JM Bernstein, SA Kyger and FG Hayden. Rapid diagnosis of influenza A and B by 24h fluorescent focus assays. *J Clin Microbiol* 26:1263-1266, 1988.
52. Herold DA, PK Anonick, M Kinter and FG Hayden. Measurement of rimantadine in plasma by capillary gas chromatography/mass spectrometry with a deuterium-labeled internal standard. *Clin Chemistr* 34:1597-1599, 1988.
53. Sperber SJ, PA Levine, DJ Innes, SE Mills and FG Hayden. Tolerance and efficacy of recombinant interferon-beta_{serine} in healthy adults. *J Infect Dis* 158:166-175, 1988.
54. Gaffey MJ, FG Hayden, JC Boyd and JM Gwaltney Jr. Ipratropium bromide treatment of experimental rhinovirus infection. *Antimicrob Agents Chemother* 32:1644-1647, 1988.
55. Hayden FG, JM Gwaltney Jr and RJ Colonno. Modification of experimental rhinovirus colds by receptor blockage. *Antiviral Res* 9:233-247, 1988.
56. Tominack RL, RJ Wills, LE Gustavson and FG Hayden. Multiple-dose pharmacokinetics of rimantadine in elderly adults. *Antimicrob Agents Chemother* 32:1813-1819, 1988.
57. Hayden FG, DJ Innes, SE Mills and PA Levine. Intranasal tolerance and histopathologic effects of a novel synthetic interferon, rIFN- Con₁. *Antiviral Res* 10:225-234, 1988.
58. Whitley RJ, Corey L, Arvin A, Lakeman FD, Sumaya CV, Wright PF, Dunkle LM, Steele RW, Soong SJ, Nahmias AJ, Alford CA, Powell DA, Joaquin VS, and the NIAID Collaborative Antiviral Study Group [F.G. Hayden]. Changing presentation of herpes simplex virus infection in neonates. *J Infect Dis* 158:109-116, 1988.
59. Hayden FG, DL Kaiser and JK Albrecht. Intranasal interferon alfa-2b treatment of naturally occurring common colds. *Antimicrob Agents Chemother* 32:224-230, 1988.
60. Sperber SJ, JV Sorrentino, DK Riker and FG Hayden. Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. *Bull N Y Acad Med* 65:145-160, 1989.
61. Hsia J, GL Simon, N Higgins, AL Goldstein and FG Hayden. Immune modulation by aspirin during experimental rhinovirus colds. *Bull N Y Acad Med* 65:45-56, 1989.
62. Sperber SJ and FG Hayden. Comparative susceptibility of respiratory viruses to recombinant alfa-2 and beta interferon. *J Interferon Res* 9:285-293, 1989.
63. McBride TP, WJ Doyle, FG Hayden and JM Gwaltney, Jr. Alteration of eustachian tube, middle ear and nose in rhinovirus infection. *Arch. Otolaryn-Head and Neck Surg* 115:1054-1059, 1989.
64. Sperber SJ, PA Levine, JV Sorrentino, DK Riker and FG Hayden. Ineffectiveness of recombinant interferon-beta_{serine} nasal drops for prophylaxis of natural colds. *J Infect Dis* 160:700-705, 1989.
65. Whitley RJ, CG Cobbs, CA Alford, SJ Soong, MS Hirsch, JD Connor, L Corey, DF Hanley, M Levin, DA Powell, and the NIAID Collaborative Antiviral Study Group, [FG Hayden]. Diseases that mimic herpes simplex encephalitis: diagnosis, prevention, and outcome. *J Amer Med Assoc* 262:234-239, 1989.
66. Hsia J, MB Szein, PH Naylor, GL Simon, AL Goldstein and FG Hayden. Modulation of thymosin_α and thymosin β₄ levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds. *Lymphokine Res* 8:383-391, 1989.

Bibliography

67. Sperber SJ and Hayden FG. Protective effect of rhinovirus receptor blocking antibody in human fibroblast cells. *Antiviral Res* 12:231-238, 1989.
68. Hayden FG, RB Belshe, RD Clover, AJ Hay, MG Oakes, and W Soo. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. *N Engl J Med* 321:1696-1702, 1989.
69. Hayden FG, BR Rollins, and AJ Hay. Anti-influenza virus activity of the compound LY253963. *Antiviral Res* 14:25-38, 1990.
70. Hsia J, AL Goldstein, GL Simon, M Szein, and FG Hayden. Interleukin-2 and interferon-production, NK activity and antigen-stimulated blastogenesis during experimental rhinovirus colds. *J Infect Dis* 162:591-597, 1990.
71. Farr BM, JM Gwaltney, Jr., JO Hendley, FG Hayden, RM Naclerio, T McBride, WJ Doyle, JV Sorrentino, and D Proud. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. *J Infect Dis* 162:1173-77, 1990.
72. Crump CE, BS Rollins, and FG Hayden. In vitro antiviral activity and cytotoxicity of aspirin: Lack of selective activity against influenza A virus or rhinovirus. *Antiviral Chemistry and Chemotherapy* 1:217-221, 1990.
73. Soong S, NE Watson, GR Caddell, CA Alford, RJ Whitley, and the NIAID Collaborative Antiviral Study Group [FG Hayden]. Use of brain biopsy for diagnostic evaluation of patients with suspected herpes simplex encephalitis: A statistical model and its clinical implications. *J Infect Dis* 163:17-22, 1991.
74. Whitley R, A Arvin, C Prober, L Corey, S Burchett, S Plotkin, S Starr, R Jacobs, D Powell, A Nahmias, C Sumaya, K Edwards, C Alford, G Caddell, S Soong, and the NIAID Collaborative Antiviral Study Group [FG Hayden]. Predictors of morbidity in neonates with herpes simplex virus infections. *N Engl J Med* 324:450-454, 1991.
75. Whitley R, A Arvin, C Crober, S Burchett, L Corey, D Powell, S Plotkin, S Starr, C Alford, J Connor, R Jacobs, A Nahmias, S Soong, and the NIAID Collaborative Antiviral Study Group [FG Hayden]. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. *N Engl J Med* 324:444-449, 1991.
76. Arruda E, FG Hayden, JF McAuliffe, MA de Sousa, SB Mota, MI McAuliffe, FC Geist, Carvalho, MC Fernandes, RL Guerrant, and JM Gwaltney, Jr. Acute Respiratory viral illness in ambulatory children of urban northeast Brazil: Importance of rhinovirus. *J Infect Dis* 164:252-58, 1991.
77. Arruda E, TE Mifflin, JM Gwaltney, Jr, B Winther, and FG Hayden. Localization of rhinovirus replication in vitro with in situ hybridization. *J Med Virol* 34:38-44, 1991
78. Sweet C, FG Hayden, KJ Jakeman, S Grambas, and AJ Hay. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. *J Infect Dis* 164:969-72, 1991.
79. Hayden FG, SJ Sperber, RB Belshe, RD Clover, AJ Hay, and S Pyke. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. *Antimicrob Agents Chemother* 35:1741-47, 1991.
80. Hechemy KE, JA Fox, DHM Groschel, FG Hayden, and RP Wenzel. Immunoblot studies to analyze antibody to the Rickettsia typhi group antigen in sera from patients with acute febrile cerebrovasculitis. *J Clin Microbiol* 29:2559-2565, 1991.
81. Whitley RJ, JW Gnann Jr, D Hinthorn, C Liu, R Pollard, F Hayden, G Mertz, M Oxman, SJ Soong, and the NIAID Collaborative Antiviral Study Group [FG Hayden]. Disseminated herpes zoster in the immunocompromised host: A comparative trial of acyclovir and vidarabine. *J Infect Dis* 165:450-5, 1992.

Bibliography

82. Sperber SJ, BV Smith, and FG Hayden. Serologic response and tolerability to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. *Antiviral Res* 17:213-222, 1992.
83. Hayden FG, K Andries, and PAJ Janssen. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. *Antimicrob Agents Chemother* 36:727-32, 1992.
84. Gwaltney JM, O Hendley, FG Hayden, K McIntosh, FB Hollinger, JL Melnick, and RB Turner. Updated recommendations for safety-testing of viral inocula used in volunteer experiments on rhinovirus colds. *Prog Med Virol* 39:256-63, 1992.
85. Arruda E, CE Crump, SD Marlin, VJ Merluzzi, and FG Hayden. In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1. *Antimicrob Agents Chemother* 36:1186-91, 1992.
86. Sperber SJ, JO Hendley, FG Hayden, DK Riker, JV Sorrentino, and JM Gwaltney, Jr. Effects of naproxen in experimental rhinovirus colds. *Ann Intern Med* 117:37-41, 1992.
87. Balfour, HH, HA Rotbart, S Feldman, LM Dunkle, HM Feder, CG Prober, GF Hayden, S Steinberg, RJ Whitley, L Goldberg, MP McGuirt and the Collaborative Acyclovir Varicella Study Group [FG Hayden]. Acyclovir treatment of varicella in otherwise healthy adolescents. *J Pediatr* 120:627-33, 1992.
88. Winther B, DJ Innes, J Bratsch, and FG Hayden. Lymphocyte subsets in the nasal mucosa and peripheral blood during experimental rhinovirus infection. *American J Rhinol* 6:149-56, 1992.
89. Sperber, SJ, WJ Doyle, TP McBride, JV Sorrentino, DK Riker, JM Gwaltney, Jr., and FG Hayden. Otolgic effects of intranasal interferon- β serine treatment of experimental rhinovirus colds. *Arch Otolaryngol - Head and Neck Surgery* 118:933-36, 1992.
90. Turner BW, WS Cail, JO Hendley, FG Hayden, WJ Doyle, JV Sorrentino, and JM Gwaltney, Jr. Physiologic abnormalities in the paranasal sinuses during experimental rhinovirus colds. *J Allergy Clin Immunol* 90:474-8, 1992.
91. Parekh, HH, KT Cragun, FG Hayden, JO Hendley, and JM Gwaltney, Jr. Nasal mucus weights in experimental rhinovirus infection. *American J Rhinol* 6:107-10, 1992.
92. Stone AA, DH Bovbjerg, JM Neale, A Napoli, H Valdimarsdottir, D Cox, FG Hayden, and JM Gwaltney, Jr. Development of common cold symptoms following experimental rhinovirus infection is related to prior stressful life events. *Behavioral Medicine* 18:115-120, 1992.
93. Turner RB, FJ Dutko, NH Goldstein, G Lockwood, and FG Hayden. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. *Antimicrob Agents Chemother* 37:297-300, 1993.
94. Jernigan JA, BS Lowry, FG Hayden, SA Kyger, BP Conway, DHM Groschel, and BM Farr. Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: Risk factors and control. *J Infect Dis* 167:1307-13, 1993.
95. Rollins BS, AHA Elkatieb, and FG Hayden. Comparative anti-influenza virus activity of 2'-deoxy-2'-fluororibosides in vitro. *Antiviral Res* 21:357-68, 1993.
96. Elkatieb AA, G Hipkind, D Woerner, and FG Hayden. Middle ear abnormalities during natural rhinovirus colds in adults. *J Infect Dis* 168:618-21, 1993.
97. Duff AL, ES Pomeranz, LE Gelber, GW Price, H Farris, FG Hayden, TAE Platts-Mills, and PW Heymann. Risk factors for acute wheezing in infants and children: Viruses, passive smoke, and IgE antibodies to inhalant allergens. *Pediatrics* 92:535-40, 1993.

Bibliography

98. Crump, CE, E Arruda, and FG Hayden. In vitro inhibitory activity of sICAM-1 for the numbered serotypes of human rhinovirus. *Antiviral Chem Chemother* 4:323-27, 1993.
99. Arruda E and FG Hayden. Detection of human rhinovirus RNA in nasal washings by PCR. *Molecular Cellular Probes* 7:373-79, 1993.
100. Doyle, WJ, DK Riker, TP McBride, FG Hayden, JO Hendley, JD Swarts, TJ Witek, Jr., JV Sorrentino, and JM Gwaltney, Jr. Therapeutic effects of an anti-cholinergic/sympathomimetic combination in induced rhinovirus colds. *Ann Otol Rhinol Laryngol* 102:521-27, 1993.
101. Arruda, E, CE Crump, and FG Hayden. In vitro selection of human rhinovirus relatively resistant to soluble intercellular adhesion molecule-1. *Antimicrob Agents Chemother* 38:66-70, 1994.
102. Doyle WJ, DP Skoner, FG Hayden, CA Buchman, JT Seroky, and P Fireman. Nasal and otologic effects of experimental influenza A virus infection. *Ann Otol Rhinol Laryngol* 103:59-69, 1994.
103. Hayden, FG, AR Tunkel, JJ Treanor, RF Betts, S Allerheiligen, and J Harris. Oral LY 217896 for prevention of experimental influenza A virus infection and illness in humans. *Antimicrob Agents Chemother* 38:1178-81, 1994.
104. Crump CE, E Arruda, and F Hayden. Comparative anti-rhinoviral activity of soluble intercellular adhesion molecule-a (sICAM-1) and chimeric ICAM-1/IgA molecule. *Antimicrob Agents Chemother* 38:1425-27, 1994.
105. Hayden FG, BS Rollins, and LK Madren. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. *Antiviral Res* 25:123-31, 1994.
106. Hayden FG, GJ Hipskind, DH Woerner, GF Eisen, M Janssens, PAJ Janssen, and K Andries. Intranasal pirodavis (R77,975) treatment of rhinovirus colds. *Antimicrob Agents Chemother* 39:290-94, 1995.
107. Madren LK, C Shipman, Jr., and FG Hayden. In vitro inhibitory effects of combinations of anti-influenza agents. *Antiviral Chemistry and Chemotherapy* 6:109-13, 1995.
108. Arruda E, TR Boyle, B Winther, DC Pevear, JM Gwaltney, Jr., and FG Hayden. Localization of human rhinovirus in the upper respiratory tract by in situ hybridization. *J Infect Dis* 171:1329-33, 1995.
109. Buchman CA, JD Swarts, JT Seroky, N Panagiotou, F Hayden, and WJ Doyle. Otologic and systemic manifestations of experimental influenza A virus infection in the ferret. *Otolaryngol Head Neck Surg* 112:572-8, 1995.
110. Rao, SS, JO Hendley, FG Hayden, and JM Gwaltney, Jr. Symptom expression in natural and experimental rhinovirus colds. *Amer J Rhinol* 9:49-52, 1995.
111. Kuter, BJ, A Ngai, CM Patterson, BO Staehle, I Cho, H Matthews, PJ Provost, CJ White, and the Oka/Merck Varicella Vaccine Study Group [FG Hayden]. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. *Vaccine* 13:967-72, 1995.
112. Klimov AI, E Rocha, FG Hayden, PA Shult, LF Roumillat, and NJ Cox. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by PCR-restriction analysis. *J Infect Dis* 172:1352-5, 1995.
113. Buchman CA, WJ Doyle, DP Skoner, C Post, CM Alper, JT Seroky, K Anderson, RA Preston, FG Hayden, P Fireman, and GD Ehrlich. Influenza A virus-induced acute otitis media. *J Infect Dis* 172:1348-

Bibliography

- 51, 1995.
114. Hayden FG, JJ Treanor, RF Betts, M Lobo, JD Esinhart, and EK Hussey. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. *J Amer Med Assoc* 275:295-299, 1996.
 115. Hayden FG, CA Sable, JD Connor, and J Lane. Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. *Antiviral Therapy* 1:51-56, 1996.
 116. Blumberg EA, C Albano, T Pruett, R Isaacs, J Fitzpatrick, J Bergin, C Crump, and FG Hayden. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. *Clin Infect Dis* 22:295-302, 1996.
 117. Doyle WJ, DP Skoner, Y Igarashi, F Hayden, AP Kaplan, MA Kaliner, and P Fireman. Pattern of nasal secretions using experimental influenza virus infection. *Rhinology* 34:2-8, 1996.
 118. Adal KA, RH Flowers, AM Anglim, FG Hayden, MG Titus, BJ Coyner, and BM Farr. Prevention of nosocomial influenza. *Infect Contl Hosp Epidemiol* 17:641-648, 1996.
 119. Hayden FG, L Diamond, PB Wood, DC Korts, and MT Wecker. Effectiveness and safety of intranasal ipratropium bromide in common colds. *Ann Intern Med* 125:89-97, 1996.
 120. Whitley RJ, H Weiss, JW Gnann, Jr., S Tying, L Sherrill, R Pollard, GJ Mertz, PG Pappas, CJ Schlepner, F Hayden, J Wolfe, S-J Soong, and the National Institute of Allergy and Infectious Diseases and Collaborative Antiviral Study Group. Acyclovir with and without prednisone for the treatment of herpes zoster: A randomized, placebo-controlled trial. *Ann Intern Med* 125:376-83, 1996.
 121. Arruda E, CE Crump, BS Rollins, A Ohlin, and FG Hayden. Comparative susceptibility of human embryonic fibroblasts and HeLa cells for isolation of human rhinoviruses. *J Clin Microbiol* 34:1277-79, 1996.
 122. Gustafson LM, D Proud, JO Hendley, FG Hayden, and JM Gwaltney, Jr. Oral prednisone therapy in experimental rhinovirus infections. *J Allergy Clin Immunol* 97:1009-14, 1996.
 123. Turner JC, Hayden FG, Lobo MC, Ramirez CE, and Murren D. Epidemiologic evidence for Lancefield Group C Beta-Hemolytic Streptococci as a cause of exudative pharyngitis in college students. *J Clin Microb* 35:1-4, 1997.
 124. Pitkäranta A, Arruda E, Malmberg H, and Hayden FG. Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. *J Clin Microb* 35:1791-93, 1997.
 125. Hayden FG, Osterhaus A, Treanor JJ, Fleming DM, Aoki FY, Nicholson G, Bohnen AM, Hirst HM, Keene O, and Wightman K for the GG167 Influenza Study Group. Efficacy and safety of the neuraminidase inhibitor zanamivir (GG167) in the treatment of influenza virus infections. *New Engl J Med* 337(13):874-9, 1997.
 126. Walker JB, Hussey EK, and Hayden FG. Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. *J Infect Dis* 176:1417-22, 1997.
 127. Arruda E, Pitkäranta A, Witek TJ, Doyle CA, and Hayden FG. Frequency and natural history of rhinovirus infections in adults during autumn. *J Clin Microb* 35:2864-68, 1997.
 128. Hayden FG, Fritz RS, Lobo MC, Alvord WG, Strober W, and Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection: Relation to symptom formation and host defense. *J Clin Invest* 101:643-649, 1998.

Bibliography

129. Doyle WJ, Skoner DP, Patel A, and Hayden FG. Effect of rimantadine on induced specific serum haemagglutination-inhibiting antibody and nasal IgA titres after experimental exposure of adults to influenza A virus. *Antiviral Therapy* 3:19-23, 1998.
130. Belshe RBN, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M, Reisinger K, Block SL, Wittes J, and Rabinovich R. Efficacy of trivalent live attenuated intranasal influenza vaccine in children. *N Eng J Med* 338:1405-1412, 1998.
132. Pitkaranta A, Hayden FG, Korts D, and Wecker M. Combined intranasal ipratropium bromide and oxymetazoline in experimental rhinovirus infection. *Am J Rhinology* 12:125-129, 1998.
133. Pitkaranta A, Virolainen A, Hero J, Arruda E, and Hayden FG. Detection of rhinovirus, respiratory syncytial virus and coronavirus infections in acute otitis media by reverse transcriptase-polymerase chain reaction. *Pediatr* 102:291-295, 1998.
134. Stilianakis NI, Perelson AS, and Hayden FG. Emergence of drug resistance during an influenza epidemic: Insights from a mathematical model. *J Infect Dis* 177:863-73, 1998.
135. Doyle WJ, Skoner DP, Alper CM, Allen G, Moody SA, Seroky JT, and Hayden FG. Effect of rimantadine treatment on clinical manifestations on otological complications in adults experimentally infected with influenza A (H1N1) virus. *J Infect Dis* 177:1260-5, 1998.
136. Bertino JS Jr., Thoelen S, VanDamme P, Bryan JP, Becherer PR, Frey S, Hayden FG, Marcus LC, Parenti DM, Sperling M, Chan ISF, Brown L, and Nalin D. A dose response study of hepatitis A vaccine in healthy adults who are 30 years old and weigh 77 kg. *J Infect Dis* 178:1181-4, 1998.
137. Blumberg, EA, Fitzpatrick J, Stutman PC, Hayden FG, and Brozena SC. Safety of influenza vaccine in heart transplant recipients. *Journal of Heart and Lung Transplantation*. 17:1075-80, 1998.
138. Pitkaranta A, Jero J, Arruda E, Virolainen A and Hayden FG. Polymerase chain reaction-based detection of rhinovirus, respiratory syncytial virus and coronavirus in otitis media with effusion. *J Pediatr* 133:390-4, 1998.
139. Gentile DA, Whiteside T, Fireman P, Hayden FG, Doyle W, and Skoner DP. Increased interleukin-6 levels in nasal lavages following experimental influenza A viral infection. *Clin Diagn Lab Immunol* 5:604-608, 1998.
140. Murphy AW, Platts-Mills TAE, Lobo M, and Hayden F. Respiratory nitric oxide levels in experimental human influenza. *Chest* 114(2):452-56, 1998.
141. Rotbart HA, Brennan PJ, Fife KH, Romero JR, Griffin JA, McKinlay MA, and Hayden FG. Enterovirus meningitis in adults. *CID* 27:896-8, 1998
142. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. *N Engl J Med* 341:1336-43, 1999.
143. Turner RB, Wecker MT, Pohl G, Witek RJ, McNally E, St.George R, Winther B, and Hayden FG. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection. *J Amer Med Assoc* 281:1797, 1999.
144. Fritz RS, Hayden FG, Calfee DP, Cass LMR, Peng AW, Alvord WG, Strober W, and Straus SE. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-

Bibliography

- controlled trial of intravenous zanamivir treatment. *J Infect Dis* 180:586-93, 1999.
145. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, and Straus SE. Use of oral neuraminidase inhibitor oseltamivir in experimental human influenza. *J Amer Med Assoc* 282:1240-1241, 1999.
 146. Calfee DP, Peng AW, Hussey EK, Lobo M, and Hayden FG. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. *Antiviral Therapy* 4:143-149, 1999.
 147. Rakes GP, Aruda E, Ingram JM, Hoover GE, Zanbrano JC, Hayden FG, Platts-Mills TAE, Heymann PW. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. *Amer J Resp Crit Care Med* 159:785-90, 1999.
 148. Treanor JJ, Hayden FG, Vrooman PS, Barbarash RB, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, and Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. *J Amer Med Assoc* 283:1016-24, 2000.
 149. Belshe RB, Cruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, and Wolff M. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. *J Pediatr* 136:168-175, 2000.
 150. Kaiser L, Henry D, Flack NP, Keene O, and Hayden FG. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. *Clin Infect Dis* 30:587-9, 2000.
 151. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, Kotloff K, King J, Piedra PA, Block SL, Yan L, and Wolff M. Correlates of immune protection induced by live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. *J Infect Dis* 181:1133-7, 2000.
 152. Hayden FG, Jennings L, Robson R, Schiff G, Jackson H, Rana B, McClelland G, Ipe D, Roberts N, and Ward P. Oral oseltamivir in human experimental influenza B infection. *Antiviral Therapy* 5:205-13, 2000.
 153. Kaiser L, Keene ON, Hammond J, Elliott M, and Hayden FG. Impact of zanamivir on antibiotics use for respiratory events following acute influenza in adolescents and adults. *Arch Int Med* 160:3234-3240, 2000.
 154. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliott MJ, Hammond JM, Sharp SJ and Ossi MJ. Inhaled zanamivir for preventing influenza in families. *N Engl J Med* 343:1282-89, 2000.
 155. Kaiser L, Crump CE, and Hayden FG. In vitro activity of pleconaril and AG7-88 against selected serotypes and clinical isolates of human rhinovirus. *Antiviral Res* 47:215-220, 2000.
 156. Gubareva LV, Kaiser L, Matrosovich M, Soo-Hoo Y, and Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. *J Infect Dis* 183:523-531, 2001.
 157. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, and Ward P. Oral oseltamivir treatment of influenza in children. *Pediatr Infect Dis J* 20:127-33, 2001.
 158. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors. *Antiviral Research. Antiviral Res.* 53:47-61, 2002.
 159. Gubareva LV, Webster RG, Hayden FG. Comparison of the activity of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. *Antimicrob Agents and Chemother* 45:3403-8, 2001.

Bibliography

160. Hayden FG. Perspectives on antiviral use during pandemic influenza. The Royal Society, Phil. Trans. R. Soc. Lond. B 356:1877-1884, 2001.
161. Winther B, Arruda E, Witek TJ, Marlin SD, Tsianco MM, Innes DJ, Hayden FG. Expression of ICAM-1 in nasal epithelium and levels of soluble ICAM-1 in nasal lavage fluid during human experimental rhinovirus infection.. Archives of Otolaryngology-Head & Neck Surgery (in press).
162. Winther B, Hayden FG, Arruda E, Dutkowski R, Ward P, Hendley JO. Viral respiratory infection in school children: effects on middle ear pressure. Pediatrics (in press).

Bibliography

Books

1. Richmond DD, Whitley RJ, Hayden F G, (eds). *Clinical Virology*, Churchill Livingstone, 1997.

Chapters

1. Hayden FG and RG Douglas Jr. Antiviral Agents. In: GL Mandell, RG Douglas Jr, and JE Bennett (ed.), *Principles and Practices of Infectious Diseases*. John Wiley & Sons, New York, 1979, pp. 353-369.
2. Gwaltney JM Jr and FG Hayden. The nose and infection. In: D Proctor and I Andersen (eds.), *The Nose: Upper Airway Physiology and Atmospheric Environment*. Elsevier Biomedical Press, Amsterdam, 1982, pp. 399-422.
3. Hayden FG. Antiviral Chemotherapy. In: LE Cluff and JE Johnson III (eds.), *Clinical Concepts of Infectious Diseases*, 3rd edition. Williams & Williams Co., Baltimore, 1982, pp 290-297.
4. Hayden FG. Coronaviruses. In: JH Stein (ed.), *Internal Medicine*, Little Brown and Co., Boston, 1983, pp 1272-1273.
5. Hayden FG and SA Halperin. Paramyxoviruses. *Ibid.* pp 1265-1272.
6. Magnussen CR, FG Hayden, and WM Valenti. Laboratory aids. In: RE Resse and RG Douglas Jr (ed.), *A Practical Approach to Infectious Diseases*. Little Brown and Co., Boston, 1983, pp 19-49.
7. Hayden FG and RG Douglas Jr. Antiviral agents. In: GL Mandell, RG Douglas Jr, and FE Bennett (eds.), *Principles and Practices of Infectious Diseases*. 2nd Ed., John Wiley and Sons, New York, 1985, pp 270-286.
8. Hayden FG. Herpes simplex virus infections. In: RF Edlich and DA Spyker (eds.), *Current Emergency Therapy - 1985*. Aspen Systems Corp., Rockville, 1985, pp 488-492.
9. Hayden FG. Clinical applications of antiviral agents for chemoprophylaxis and therapy of respiratory viral infections. In: A Billiau, E deClercq, and H Schellekens (eds.), *Antiviral Research, Supplement 1*. Elsevier Science Publishers B.V., Amsterdam, 1985, pp 229-239.
10. Hayden FG, OL Laskin, and RG Douglas Jr. Chapter 11. Susceptibility testing of viruses and pharmacodynamics of antiviral agents. In: V Lorian (ed.), *Antibiotics in Laboratory Medicine*. 2nd Ed. Williams and Wilkins, Baltimore, 1986, pp 359-380.
11. Hayden FG. Animal models in influenza for evaluation of antiviral agents. In: O Zak and M Sande (eds.), *Animal Models in the Evaluation of Chemotherapy*. Academic Press, Inc., London, 1986, pp 353-371.
12. Hayden FG. Use of interferons for prevention and treatment of respiratory viral infections. In: J Mills and L Corey (eds.), *Antiviral Chemotherapy: New Directions for Clinical Application and Research*. Elsevier Scientific Publishing Co., Inc., New York, 1986, pp 28-39.
13. Hayden FG. Combinations of antiviral agents for treatment of influenza virus infections. In Oxford JS, Field HJ, and Reeves DS (eds). *Drug Resistance in Viruses, Other Microbes, and Eukaryotes*, Academic Press, London, 1986, pp 177-183.
14. Hayden FG and MJ Gaffey. Paramyxovirus infections (parainfluenza, mumps, measles, respiratory syncytial virus). Chapter 235 In: JH Stein (ed.), *Internal Medicine*. 2nd Edition, Little Brown and Co., Boston, 1987, pp 1578-1586.

Bibliography

15. Hayden FG and MJ Gaffey. Coronavirus infections. Chapter 236 In: JH Stein (ed.) Internal Medicine. 2nd Edition, Little Brown and Co., Boston, 1987, pp 1586-1591.
16. Tominack RL and FG Hayden. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. In: V Knight (ed.), Antiviral Chemotherapy, Infectious Disease Clinics of North America, WB Saunders, Co., Philadelphia, 1:459-478, 1987.
17. Sperber SJ and FG Hayden. Antiviral chemotherapy and prophylaxis of viral respiratory disease. In: WL Drew (ed.), Clinics in Laboratory Medicine, WB Saunders, Philadelphia, 7:869-896, 1987.
18. Hayden FG and JM Gwaltney Jr. Viral infections. In: LF Murray and JA Nadell (eds.), Textbook of Respiratory Medicine, WB Saunders, Philadelphia, 1988, pp 748-802.
19. Hayden FG. Intranasal interferons for control of respiratory viral infections. In: M Revel (ed.), Clinical Aspects of Interferon, Kluwer Academic Publishers, Boston, 1988, pp 3-16.
20. Sperber SJ and FG Hayden. Perspectives in the use of antiviral agents for the prevention and treatment of respiratory viral infections. In: E DeClercq (ed.), Clinical Use of Antiviral Drugs, Martinus Nijhoff Publishing, Boston, 1988, pp 317-340.
21. Hayden FG and RG Douglas Jr. Antiviral agents. Chapter 34. In: GL Mandell, RG Douglas Jr, and JE Bennett (eds.), Principles and Practices of Infectious Diseases. 3rd Edition. Churchill Livingstone, Inc., New York, 1989, pp 370-393.
22. Hayden FG. Interferons. Chapter 35. In: GL Mandell, RG Douglas Jr, and JE Bennett (eds.), Principles and Practices of Infectious Diseases. 3rd Edition. Churchill Livingstone, Inc., New York, 1989, pp 393-398.
23. Hayden FG. Update on antiviral chemotherapy of respiratory viral infections. In: L Corey and J Mills (eds.), Antiviral Chemotherapy: New Directions for Clinical Application and Research, Vol. 2. Elsevier Scientific Publishing Co., Inc., New York, 1989, pp 117-142.
24. Gaffey MJ and FG Hayden. Paramyxovirus and coronavirus infection. Chapter 185. In: JH Stein, (eds.), Internal Medicine, 3rd Edition, Little Brown and Co., Boston, 1989, pp 1371-79.
25. Hayden FG and Hay AJ. Emergence and transmission of drug-resistant influenza A viruses. In: JJ Holland (ed.) Current Topics in Microbiology and Immunology, Vol 176: Genetic Diversity of RNA Viruses. Springer-Verlag, Berlin, 1992, pp 119-129.
26. Arruda E and FG Hayden. Rhinoviruses. In: J Lederberg (ed.), Encyclopedia of Microbiology. Vol 3, Academic Press, Orlando, Florida, 1992, pp. 555-64.
27. Hayden FG and RB Couch. Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine. In: C Hannoun, Kendal AP, Klenk HD, and Ruben FL (eds.), Options for the Control of Influenza II. Elsevier Science Publishers, Amsterdam, The Netherlands, 1993, pp. 333-42.
28. Hayden FG. Update on treatment of respiratory viral infections. In: J Mills and L Corey (eds.) Antiviral Chemotherapy: New Directions for Clinical Application and Research, Vol. 3. PTR Prentice Hall, New Jersey, 1993, pp. 207-228.
29. Arruda E and FG Hayden. Role of cytokines in viral infections. In: A Gearing, J Rossio, JJ Oppenheim (eds.) Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis and Therapy. Oxford University Press, Oxford, 1993, pp. 79-92.
30. Hayden FG and GF Hayden. Paramyxovirus (Measles, Parainfluenza, Mumps, and Respiratory Syncytial

Bibliography

- Virus), Rubella Virus, and Coronavirus Infections, Chapter 246. In: JH Stein (ed.) Internal Medicine, Fourth Edition, Mosby-Year Book, Inc., St. Louis, 1994, pp. 2000-12.
31. Arruda E and FG Hayden. Clinical studies of antiviral agents for picornaviral infections. Chapter 12. In: DJ Jeffries and E de Clercq (eds.) Antiviral Chemotherapy. John Wiley & Sons, Chichester, UK, 1995, pp. 321-55.
 32. Hayden FG and JM Gwaltney, Jr. Viral Infections, Chapter 33. In: JF Murray and JA Nadell (eds). Textbook of Respiratory Medicine, Second Edition, WB Saunders, Philadelphia, PA, 1994, pp 977-1035.
 33. Hayden FG. Antiviral agents. Chapter 32. In: GL Mandell, JE Bennett, and R. Dolin (eds.), Principles and Practices of Infectious Diseases. 4th Edition. Churchill Livingstone, Inc., New York, NY, 1995, pp 411-450.
 34. Sable CA and FG Hayden. Orthomyxoviral and paramyxoviral infections in transplant patients. In: R Rubin (ed.) Infectious Disease Clinics of North America: Infection in Transplantation, WB Saunders, Philadelphia, PA, 1995, pp 987-1003.
 35. Hayden FG. Antiviral agents, Chapter 50. In: JG Hartman and LE Limbird (eds.), Goodman and Gilman's The Pharmacologic Basis of Therapeutics, Ninth Edition, McGraw Hill, New York, NY, 1996, pp 1191-1223.
 36. Arruda E, FC Geist, MI McAuliffe, and FG Hayden. Viral respiratory tract illnesses in developing tropical area: prospective studies in Goncalves Dias, Fortaleza, Brazil. Chapter 11. In: RL Guerrant, MA de Souza, MK Nations (eds.) At the Edge of Development: Health Crisis in a Transitional Society. Carolina Academic Press, 1996, pp 203-223.
 37. Hayden FG. Influenza, Chapter 332. In: JC Bennett and F Plum (eds.) Cecil Textbook of Medicine, 20th Edition, WB Saunders Company, Philadelphia, PA 1996, pp 1753-57.
 38. Hayden FG. Amantadine and rimantadine resistance in influenza viruses, Chapter 4. In: D Richman (ed.), Antiviral Drug Resistance. J Wiley and Sons, Inc., Chichester, UK 1996, pp 59-77.
 39. Arruda E and FG Hayden. Update on therapy of influenza and rhinovirus infections. In: J Mills, PA Volberding, and L Corey (eds.). Antiviral Chemotherapy 4: New Directions for Clinical Application and Research, Advances in Experimental Medicine and Biology 314:175-87, Plenum Press, New York, 1996.
 40. Hayden FG, Lobo M, Hussey EK, and Eason CU. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. In: LE Brown, AW Hampson and RG Webster (eds.). Options for the control of influenza III, Elsevier Science B.V., Amsterdam, The Netherlands, 1996, pp 718-25.
 41. Hayden FG and PA Palese. Influenza Virus. Chapter 39 In: DD Richmond, RJ Whitley, FG Hayden (eds.), Clinical Virology. Churchill Livingstone, New York, NY, 1997, pp 911-942.
 42. Hayden FG and Aoki FY. Amantadine, rimantadine, and related agents. In: Yu V, Merigan T, and Barriere S (eds). Antimicrobial Therapy and Vaccines, Williams & Wilkins, Baltimore, MD, 1999, pp 1344-1365.
 43. Treanor JJ and Hayden FG. Experimental influenza in humans. In: Nicholson K, Webster R, and Hay A. (eds) Textbook of Influenza, Blackwell Healthcare Communications, London, UK. 1998, pp 517-537.
 44. Arruda E and Hayden FG. Paramyxovirus (Parainfluenza, mumps, measles, and respiratory syncytial virus), rubella virus, coronavirus, and adenovirus infections. Chapter 251. In: JH Stein (ed.) Internal Medicine, Fifth Edition, Mosby, Inc., St. Louis, MO, 1998, pp 1494-1505.

Bibliography

45. Hayden FG. Update on influenza and rhinovirus infections. In: Mills J, Volberding PA, Corey L (eds). Antiviral Chemotherapy 5 New Directions for Clinical Application and Research. Kluwer Academic/Plenum Publishers, New York, NY, 1999, pp 55-67.
46. Kaiser L, Hayden FG. Hospitalizing Influenza in Adults. In: Remington JS, Swartz MN (eds). Current Clinical Topics in Infectious Diseases, Blackwell Science, Malden, MA, 1999, pp112-134.
47. Hayden FG. Influenza. Chapter 379. In: Goldman L, and Bennett JC (eds). Cecil Textbook of Medicine, 21st Edition, W. B. Saunders Company, Philadelphia, PA, 1999, pp 1779-1800.
48. Arruda E and Hayden FG. Influenza virus, respiratory syncytial virus, parainfluenza viruses, rhinovirus, and respiratory adenoviruses. Chapter 104. In: Guerrant RL, Walker DH, Weller PF (eds). Tropical Infectious Diseases Principles, Pathogens, & Practice, Churchill Livingstone, Philadelphia, PA, 1999, pp 1109-1121.
49. Treanor JJ and Hayden FG. Viral Infections. Chapter 32. In: Murray JF, Nadel JA (eds). Textbook of Respiratory Medicine, Third Edition, W.B. Saunders Company, Philadelphia, PA, 2000, pp. 929-984.
50. Hayden, FG. Antimicrobial agents. Chapter 50. In : Hardman JG and Limbird LE (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th Edition, McGraw-Hill, New York, 2001, pp1313-1347.

Bibliography

Invited Reviews

1. Van Voris LP, J Bartram, and FG Hayden. Pharmacokinetics of amantadine and rimantadine. *Microbiology* - 1984. American Society for Microbiology, Washington, DC., pp 421-423, 1984.
2. Hayden FG. Recombinant interferon for prophylaxis and therapy of rhinovirus and influenza virus infections. *Microbiology* - 1984. American Society for Microbiology, Washington, DC., pp 409-412, 1984.
3. Powers RD and FG Hayden. Herpesvirus infection: Current antiviral therapy. *Hospital Formulary* 19:1040-1045, 1984.
4. Hayden FG, AN Schlepukhin, and NL Pushkarskaya. Combined interferon- α_2 , rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication *in vitro*. In: RA Smith, V Knight, and JA Smith (eds.), *Clinical Applications of Ribavirin*. Academic Press, Orlando, pp 39-48, 1984.
5. Scheibel SF and FG Hayden. Stay alert for the serious sequelae of influenza. *J Resp Dis* 6:21-29, 1985.
6. Hayden FG. Recombinant interferon- α_2 for prevention and treatment of respiratory viral infections. In: R Kono and A Nakajima (eds.), *Herpes Viruses and Viral Chemotherapy*. Elsevier Science Publishers B.V., Excerpta Medica, Amsterdam, pp 325-330, 1984.
7. Hayden FG. Amantadine and rimantadine: efficacy, side effects, pharmacokinetics. *J Resp Dis* 8(suppl 11A):S45-50, 1987.
8. Sperber SJ and FG Hayden. Minireview: Chemotherapy of rhinovirus colds. *Antimicrob Agents Chemother* 32:409-419, 1988.
9. Hayden FG. An office guide to antiviral therapy. *Emergency Med* 20:155-170, 1988.
10. Sperber SJ and FG Hayden. Intranasal interferons for control of the common cold. *ISI Atlas of Science: Immunol* 1:20-24, 1988.
11. Doyle WJ, TP McBride, JD Swarts, FG Hayden and JM Gwaltney Jr. The response of the nasal airway, middle ear and eustachian tube to provocative rhinovirus challenge. *Amer J Rhinology* 2:149-154, 1988.
12. Hayden, FG. Significance of rimantadine resistance in influenza A viruses. *J Res Dis* 10:S62-S67, 1989.
13. Betts RF, FG Hayden, and A Monto. Safety and tolerance of a loading dose of rimantadine. *J Res Dis* 10:S42-S45, 1989.
14. Gwaltney JM Jr, O Hendley, FG Hayden, K McIntosh, FB Hollinger, JL Melnick and RB Turner. Updated recommendations for safety-testing of viral inocula used in volunteer experiments on rhinovirus colds. *Prog Med Virol* 39:256-63, 1992.
15. Hayden FG and RB Couch. Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine. *Rev Med Virol* 2:89-96, 1992.
16. Hayden FG. Update on antiviral agents and viral drug resistance. In: G Mandell, R Douglas Jr, J Bennett (eds.), *Supplements to Principles and Practice of Infectious Diseases*, Vol 2, No 2. Churchill Livingstone Inc., New York, 1993.
17. Hayden FG, HN Himmel, and JP Hegggers. Herpesvirus infections in burn patients. *Chest* 106:15S-21S, 1994.

Bibliography

18. Hayden FG. Amantadine and rimantadine resistance in influenza A viruses. *Current Opinion in Infectious Diseases* 7:674-77, 1994.
19. Kimberlin CS, Crumacker, SE Straus, KK Biron, WL Drew, FG Hayden, M McKinlay, DD Richman, and RJ Whitley. Antiviral resistance in clinical practice. *Antiviral Res* 26:423-38, 1995.
20. Hayden FG. Combination antiviral therapy for respiratory virus infections. *Antiviral Res* 29:45-48, 1996.
21. Hayden FG. Influenza in the elderly. *J Geriatric Drug Therapy* 10:5-23, 1996 and In: JW Cooper (ed.), *Antiviral in the Elderly*, Pharmaceutical Products Press, Binghamton, NY, 1996, pp 5-23.
22. Hayden FG. Combination antiviral therapy for respiratory virus infections. *Antiviral Res.* 29:45-48,1996.
23. Hayden FG. Antiviral agents for influenza virus infections. *Pacific Basin Respiratory Virus Research Group Newsletter.* 4:3-6,1996.
24. Hayden, FG. Antivirals for pandemic influenza. *J Infect Dis* 176(Suppl 1):S56-61, 1997.
25. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. *Am J Med* 102(3A):55-60, 1997.
26. Pitkaranta A and Hayden FG. What's New With Common Colds? Complications and Management. *Antiviral Therapy* 15:117-118, 121-122, 124-128, 1998.
27. Pitkaranta A and Hayden FG. What's New With Common Colds? Pathogenesis and Diagnosis. *Antiviral Therapy* 15:50-53, 57-59, 1998.
28. Calfee DP and Hayden FG. New approaches to influenza chemotherapy. *Drugs* 56:537-553, 1998.
29. Pitkaranta A and Hayden FG. Rhinoviruses are important respiratory pathogens. *Ann Med* 30:529-537, 1998
30. Kaiser L, Couch RB, Galasso GJ, Glezen WP, Webster RG, Wright PF, and Hayden FG. First international symposium on influenza and other respiratory viruses: summary and overview. Kapalua, Maui, Hawaii, December 4-6, 1998. *Antiviral Res* 42:149-176, 1999.
31. Gubareva LV, Kaiser L, and Hayden, FG. Influenza virus neuraminidase inhibitors. *Lancet* 355:827-835, 2000.
32. Munoz FM, Galasso GJ, Gwaltney JM Jr, Hayden FG, Murphy B, Webster R, Wright P, and Couch RB. Current research on influenza and other respiratory viruses: II International Symposium on Influenza and Other Respiratory Viruses. *Antiviral Res* 46:91-124, 2000.
33. Rotbart HA and Hayden FG. Picornavirus Infections. *Arch Fam Med* 9:913-922, 2000
34. Hayden, FG. Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention. *Vaccine* 19:S66-S70, 2001.
35. Schmidt AC, Couch RB, Galasso GJ, Hayden FG, Mills J, Murphy BR, Chanock RM. Current research on respiratory viral infections: III International Symposium on Respiratory Virus Infections. *Antiviral Res* 50:157-196; 2001.
36. Gubareva LV and Hayden FG. In: Dodet B and Vicari M (eds) *Anti-influenza drugs: implications of resistance.* *Emerging Diseases. Emergence and Control of Zoonotic Ortho- and Paramyxovirus Diseases Symposium Proceedings*, John Libbey, Paris, 2001, p121-126.

Bibliography

Other

1. Hayden FG. Editorial comment - Herpes genitalis. *Infect Control* 4:74-75, 1983.
2. Hayden FG and JM Gwaltney Jr. Letter: Efficacy of alpha₂-interferon against the common cold. *N Engl J Med* 314:144-149, 1986.
3. Hayden FG. (contributor in Infectious Disease) In: SI Landau (editor-in-chief) *International Dictionary of Medicine and Biology*. John Wiley & Sons, New York, 1986.
4. Sperber SJ and FG Hayden. Letter: Antibiotics and chronic obstructive pulmonary disease. *Ann Intern Med* 106:910, 1987.
5. Farr BM, FG Hayden and JM Gwaltney Jr. Letter: Zinc for the common cold. *Antimicrob Agents Chemother* 32:606-607, 1988.
6. Tunkel AR, JK Crane, and FG Hayden. Letter: Pulmonary Nocardiosis in AIDS. *Chest* 100:195-6, 1991.
7. Gwaltney JM, Jr. and FG Hayden. Letter: Psychological Stress and the Common Cold. *N Engl J Med* 326:644-45, 1992.
8. Hayden FG. (contributor, Task Force on Viruses) In: J Lederberg, RE Shope, and SC Oaks, Jr. (eds.) *Emerging Infections Microbial Threats to Health in the United States*. National Academy Press, Washington DC, 1992.
9. McIntosh K, P Halonen, and O Ruuskanen (FG Hayden, participant). Report of a Workshop on Respiratory Viral Infections: Epidemiology, Diagnosis, Treatment, and Prevention. *Clin Infect Dis* 16:151-64, 1993.
10. Hayden, FG. Meeting Report on IXth International Congress of Virology. *International Antiviral News* 1:141-2, 1993.
11. Participant in Report of an Informal Consultation: Progress in development and use of antiviral drugs and interferon. World Health Organization, Geneva, Switzerland, March 13-15, 1995, pp. 1-30.
12. Hayden FG. Meeting Report on Options for Control of Influenza III. *International Antiviral News* 4:112-5, 1996.
13. Hayden FG. Meeting Report: Summary of GG167 studies from the Third Options Meeting. In: *Influenza-European Scientific Working Group on Influenza* 5:6, September, 1996. Hayden FG. Letter to the Editor: Cost and the Common Cold. *Annals of Int Med* 126:173-74, 1997.
14. Pitkaranta A, Hayden FG. Respiratory Viruses and Acute Otitis Media. Letter: *N Engl J Med* 340:2001, 1999.
15. Advances in the prophylaxis and treatment of influenza illness. (Based on a presentation by Frederick G. Hayden, MD) *Am J Managed Care* 6,(5 suppl):S247-254, 2000
16. Kaiser L, and Hayden FG. Influenza: Continuing threats and new interventions. *International Reports on Community Acquired Infections* 1:1-11, 2000.
17. Hayden FG and Elliot MJ. Letter to editor: Zanamivir to prevent influenza. *N Engl J Med* 344:529-30, 2001.
18. Ison MG, Hayden FG. Commentary. *International Antiviral News* 9:24; 2001

Bibliography

Bibliography

Abstracts and Presentations

1. Hayden FG, WJ Hall, RG Douglas Jr and D Speers. Aerosolized amantadine: pharmacokinetics and safety testing of normal volunteers. Presented at the Seventeenth Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY., October 13, 1978 [abst #279].
2. Hayden FG. In: JR LaMontagne and GJ Galasso (ed.), Report of a workshop on clinical studies of the efficacy of amantadine and rimantadine against influenza virus. *J Infect Dis* 138:928-931.
3. Hayden FG, WJ Hall, RG Douglas Jr and D Speers. Therapeutic trial of aerosolized amantadine HCl in naturally acquired influenza A virus infection. Presented at the Eighteenth Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA., October 3, 1978 [abst #485].
4. VanVorris LP, FG Hayden, RF Betts, RG Douglas Jr and WA Christmas. Oral amantadine and rimantadine therapy of natural influenza A/USSR/77/H1N1. Presented at the Eighteenth Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA., October 3, 1978 [abst #483].
5. Hayden FG and RG Douglas Jr. Enhancement of activity against influenza A viruses by combinations of antivirals. Presented at the Southern Society for Clinical Investigation, New Orleans, LA., January 20, 1979. *Clinical Research* 26:799A, 1978.
6. Hayden FG, DM Zylidnikov, VI Iljenko and YV Padolka. Comparative therapeutic effect of aerosolized or oral rimantadine HCl in experimental influenza A virus infection. Presented at the Nineteenth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA., October 2, 1974 [abst #563], and presented at the Second Meeting of the USA-USSR Working Group on Influenza and Acute Respiratory Diseases, Baylor College of Medicine, Houston, TX., February 2, 1979. Published in JD Nelson and F Grassi (eds.), *Current Chemotherapy and Infectious Disease*. American Society for Microbiology, Washington, DC., 1980, pp 1348-1350.
7. Hayden FG, JM Gwaltney Jr and FL Van de Castle. Comparative toxicity of antiinfluenza drugs in healthy adults. Presented at the Southern Section American Federation for Clinical Research, New Orleans, LA., January 26, 1980. *Clinical Res* 27:751A, 1979.
8. Hayden FG, D Woerner and JM Gwaltney Jr. Prophylactic activity of intranasal enviroxime in volunteers with experimental rhinovirus type 39 infection. Presented at the Twelfth International Congress of Chemotherapy, Florence, Italy, July 22, 1981 [abst #321].
9. Hayden FG and BA Anderson. Combined rimantadine and ribavirin therapy of experimental influenza A virus infection in mice. Presented at the Fifth International Congress of Virology, Strasbourg, France, August 6, 1981 [abst #W7/10].
10. Hayden FG and JM Gwaltney Jr. Antipicornavirus activity of the nitrobenzene compound MDL860. Presented at the Twenty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL., November 5, 1981 [abst #337].
11. Hayden FG and BA Anderson. Influenza A virus strain differences in antiviral effects of rimantadine and ribavirin combinations. *Clin Res* 29:868A, 1981.
12. Hayden FG and JM Gwaltney Jr. Interferon-alpha₂ prevents experimental rhinovirus type 39 infection in adults. Presented at the Twenty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami, FL., October 4, 1982 [abst #192].
13. Hayden FG, HE Hoffman and DA Spyker. Differences in amantadine HCl side effects relate to differences in pharmacokinetics. Presented at the Twenty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami, FL., October 5, 1982 [abst #423].

Bibliography

14. Hayden FG, BA Anderson and N Pushkarskaya. Combined interferon- α_2 , rimantadine HCl, and ribavirin inhibition of influenza A virus replication. Presented at the Twenty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami, FL., October 5, 1982 [abst #444].
15. Powers RD, WM Dotson Jr and FG Hayden. Modification of virus-induced diabetes mellitus in mice by interferon or airdone. Presented at the Twenty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami, FL., October 5, 1982 [abst #448].
16. Farr BM, GL Mandell, FG Hayden and JM Gwaltney Jr. Human polymorphonuclear functions are unaffected by recombinant DNA interferon. Presented at the Southern Section American Federation for Clinical Research, New Orleans, LA., January 27, 1983. Clin Res 30:852A, 1982.
17. Powers RD, FG Hayden and JO Hendley. Prolonged survival of type 1 herpes simplex virus in lip care products. Clin Res 30:876A, 1982.
18. Clayton MT, FG Hayden, D Innes and CE Hess. Infectious mononucleosis complicated by fatal aplastic anemia. Presented at the Virginia Regional Meeting of the American College of Physicians, Williamsburg, VA., February 20, 1983. VA Med 110:119, 1983.
19. Hayden FG, SE Mills and ME Johns. Human tolerance and histopathological effects of chronic intranasal interferon- α_2 . Presented at the Second International TNO Conference on the Biology of the Interferon System, Rotterdam, The Netherland, April 22, 1983. Published in E DeMeyer and H Schellekens (eds.), The Biology of the Interferon System 1983, Elsevier Science Publishers, Amsterdam, The Netherlands, 1983, pp 463-468.
20. Hayden FG, AS Sorenson and JA Bateman. Comparison of the Immulok "Cultureset" kit and virus isolation for detection of herpes simplex virus in clinical specimens. Presented at the Sixty-seventh Meeting of the Association of Clinical Scientist, Charlottesville, VA., May 13, 1983 [abst #7].
21. Farr BM, JM Gwaltney Jr and FG Hayden. Prevention of natural rhinovirus infection by daily intranasal human interferon- α_2 . Presented at the Thirteenth International Congress of Chemotherapy, Vienna, Austria, August 31, 1983 [abst #4.7/1-8].
22. Hayden FG and JM Gwaltney Jr. Intranasal interferon α_2 therapy of experimental rhinovirus type 39 infection. Presented at the Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, NV., October 25, 1983 [abst #384].
23. Hayden FG. Prophylaxis and treatment of rhinovirus and influenza A virus infection with interferon. Presented at the Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, NV., October 24, 1983 [abst #122].
24. Van Voris LP, J Bartram, HE Hoffman, LM Shalaby, JC Gaylord, LS Davis and FG Hayden. Comparative pharmacokinetics of rimantadine hydrochloride and amantadine hydrochloride. Presented at the Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, NV., October 24, 1983 [abst #684].
25. Gwaltney JM Jr and FG Hayden. Prophylactic efficacy of intranasal RMI-15,731 in experimental rhinovirus infection. Presented at the Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, NV., October 26, 1983 [abst #931].
26. Hayden FG and JM Gwaltney Jr. Human interferon- α_2 prophylaxis and therapy of respiratory viral infections. Presented at the Sixth International Congress of Virology, Sendai, Japan, September 5, 1984 [abst #W35-1].

Bibliography

27. Hayden FG and JM Gwaltney Jr. Human interferon-alpha2 prophylaxis and therapy of respiratory infections. Presented at the Pharmacological and Clinical Approaches to Herpes Virus and Virus Chemotherapy Meeting, Oiso, Japan, September 13, 1984 [abst #VII-8].
28. Winther B, DJ Innes, SE Mills and FG Hayden. Nasal mucosal responses to recombinant leukocyte A interferon in healthy adults. Presented at the Twenty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC., October 9, 1984 [abst #919], and at the Third International TNO Meeting on the Biology of the Interferon System, Heidelberg, West Germany, October 24, 1984 [abst #E-30].
29. Salata RA, FG Hayden, J Rubenstein, DHM Groschell and RP Wenzel. Acute febrile cerebrovasculitis: clinical and laboratory features. Presented at the Twenty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC., October 10, 1984 [abst #762].
30. Geist FC and FG Hayden. Comparative sensitivity of MRC-5 fibroblast and fetal tonsil cell strain for isolation of rhinoviruses from clinical specimens. Presented at the Annual Meeting of the American Society for Microbiology, Las Vegas, NV., March 5, 1985 [abst #T1].
31. Hayden FG and HE Hoffman. Single-dose pharmacokinetics and nasal mucus penetration of amantadine HCl and rimantadine HCl in adults. Presented at Viratik-UCLA Symposium on Options for the Control of Influenza, Keystone, CO., April 21, 1985 [abst #1847], *J Cell Biochem* 9C:276, 1985.
32. Hayden FG. Clinical applications of antiviral agents for chemoprophylaxis and therapy of respiratory viral infections. Presented at the First International TNO Conference on Antiviral Research, Rotterdam, The Netherlands, May 3, 1985 [abst #49].
33. Hayden FG. Combinations of antiviral agents for treatment of influenza virus infections. Presented at the Virology Group Symposium of the British Society for Antimicrobial Chemotherapy, Bath, United Kingdom, July 5, 1985.
34. Hayden FG. Clinical studies of rimantadine hydrochloride in the United States. Presented at the D.I. Ivanosky Institute for Virology Symposium on the Molecular Biology of Hepatitis and Influenza Viruses. Moscow, USSR., September 25, 1985.
35. Hayden FG, JM Gwaltney Jr and JK Albrecht. Intranasal interferon-alpha 2 prophylaxis of respiratory illnesses in families. Presented at the Meeting of the American Federation of Clinical Research, Washington, DC., May 4, 1985, and at the TNO-ISIR Meeting on the Interferon System, Clearwater Beach, FL., October 18, 1985. *Clin Res* 33:404A, 1985.
36. Gaffey MJ, JM Gwaltney Jr, WE Dressler, JV Sorrentino and FG Hayden. Intranasal atropine methonitrate treatment of experimental rhinovirus (RV) colds. Presented at the Twenty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN., September 29 - October 3, 1985 [abst #847].
37. Gaffey MJ, SE Mills and FG Hayden. Histologic effects of intranasal interferons in mice. Presented at the TNO-ISIR Meeting on the Interferon System, Clearwater Beach, FL., October 16, 1985.
38. Hayden FG. Use of interferons for prevention and treatment of respiratory virus infections. Presented at the University of California-San Francisco Symposium, New Directions in Antiviral Chemotherapy, San Francisco, CA., November 7, 1985 [abst page #16] and the Annual Conference II of the Inter-American Society for Chemotherapy, Tampa, FL., December 9, 1985.
39. Hayden FG. Amantadine-rimantadine in influenza: clinical pharmacology. Presented at the Federation of American Societies for Experimental Biology, Seventieth Annual Meeting, St. Louis, MO., April 14, 1986.

Bibliography

40. Hayden FG, JM Gwaltney Jr and RJ Colonno. Effect of intranasal rhinovirus receptor monoclonal antibody on the course of experimentally induced rhinovirus type 39 infection in man. Presented at the Annual Meeting of the American Society for Virology, Santa Barbara, CA., June 22-26, 1986.
41. Hayden FG, DJ Innes, SE Mills and PA Levine. Long-term tolerance of intranasal recombinant interferon-beta_{ser} in man. Presented at the 1986 Annual Meeting of the International Society for Interferon Research, Espoo, Finland, September 5, 1986. *Journal of Interferon Research* 6(1):31, 1986, and In: Cantrell K, H Schellekens (eds.), *This Biology of the Interferon System 1986*, Martinus Nijhoff Publishers, Dordrecht, The Netherlands, 1987, pp 449-455.
42. Creticos CM, DS Stein, GG Jackson, J Bernstein, T Sorg, G Schiff and FG Hayden. Oral ribavirin treatment of influenza A and B. Presented at the Twenty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA., September 28 - October 1, 1986 [abst #91].
43. Geist F, JA Bateman and FG Hayden. *In vitro* activity of zinc salts against human rhinoviruses. Presented at the Twenty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA., September 28 - October 1, 1986 [abst #392].
44. Mifflin TE, J Bowden, M Lovell, J Savory, D Groschel, F Hayden, D Burns. Isolation and use of a DNA probe for rapid detection of cytomegalovirus. Presented at the American Association for Clinical Chemists, Chicago, Ill., July 17, 1986 [abst #609]. *Clinical Chemistry* 32:1172, 1986.
45. Bowden J, TE Mifflin, M Lovell, J Savory, D Groschel, F Hayden, DE Bruns. Comparison of radioisotopic and non-isotopic DNA probes for cytomegalovirus DNA. American Association for Clinical Chemistry and Canadian Society of Clinical Chemists, Chicago, Ill., July 17, 1986 [abst #620]. *Clinical Chemistry* 32:1175, 1986.
46. Hayden FG, DL Kaiser and JK Albrecht. Intranasal interferon-alfa-2b treatment of natural rhinovirus colds. Presented at the Seventh International Congress of Virology, Edmonton, Canada, August 13, 1987 [abst #R32.12, p. 218]. *Clin Res* 35:477A, 1987.
47. Sperber SJ, JM Gwaltney Jr, DL Kaiser and FG Hayden. Tolerance and efficacy of recombinant intranasal interferon-beta serine in preventing rhinovirus colds. Presented at the Meeting of the American Federation for Clinical Research, San Diego, CA., May 1-4, 1987. *Clin Res* 35:491A, 1987.
48. McBride TP, WJ Doyle, F Hayden and J Gwaltney. Eustachian tube response to a provocative rhinovirus challenge. Presented at the Fourth International Symposium on Recent Advances in Otitis Media, Bay Harbour, FL., June 1-4, 1987.
49. Sperber SJ and FG Hayden. Comparative *in vitro* activity of recombinant alpha and beta interferons against rhino- and coronavirus. Presented at the Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY., October 4-7, 1987 [abst #500].
50. Sperber SJ, JM Gwaltney Jr, JV Sorrentino and FG Hayden. Pseudoephedrine alone or combined with ibuprofen as treatment for experimental rhinovirus colds. Presented at the Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY., October 4-7, 1987 [abst #501].
51. Geist F, I McAuliffe, J McAuliffe, J Gwaltney and FG Hayden. Etiologies of acute respiratory virus infections in ambulatory children in Fortaleza, Brazil. Presented at the Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY., October 4-7, 1987 [abst #901].
52. Stokes CE, JM Bernstein, T Herchline, S Kyger and FG Hayden. Rapid diagnosis of influenza A and B by 24 hour shell vial and chamber slide fluorescent focus assays. Presented at the Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY., October 4-7, 1987 [abst #910].

Bibliography

53. Hechemy KE, JA Fox, DHM Groshell, FG Hayden and RP Wenzel. The use of immunoblot to confirm serodiagnostic test results in patients with Rickettsial diseases. Presented at the Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY., October 4-7, 1987 [abst #1247].
54. Sperber SJ, JM Gwaltney Jr, DL Kaiser and FG Hayden. Tolerance and efficacy of recombinant intranasal interferon-beta serine in preventing experimental and natural rhinovirus colds. Presented at the 1986 Annual Meeting of the International Society for Interferon Research, Washington, DC., November 2-6, 1987. *Journal of Interferon Research* 6(1):691, 1987.
55. Hayden F, D Innes, S Mills and P Levine. Intranasal tolerance of recombinant interferon-alfa Con1 in healthy volunteers. Presented at the Second International Conference on Antiviral Research, Williamsburg, VA., April 13, 1988. Program and Abstracts, *Antiviral Research*, Vol. 9, pg 122. Jan/Feb 1988.
56. Hayden FG. Antiviral chemoprophylaxis and therapy of influenza virus infections. Presented at the Antivirals-88 International Symposium: Basic and Clinical Approaches to Virus Chemotherapy, Helsinki, Finland, June 19-22, 1988. Final Program Antivirals-88, pg 67.
57. Sperber SJ, BV Smith and FG Hayden. Preliminary experience with a live and heat-inactivated varicella vaccine in healthy seropositive adults. Program and Abstracts of the Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA., October 23-26, 1988 [abst #728].
58. Harmond MW, S-P Wu, FG Hayden and AP Kendal. Development of an antiviral resistance screening assay for type A influenza viruses. Presented at the Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA., October 23-26, 1988 [abst #217].
59. Hayden FG. Treatment of respiratory viral infections. Presented at the Second Triennial Conference on New Directions in Antiviral Chemotherapy, San Francisco, CA., November 3, 1988. Syllabus, pg. 65-96.
60. Arruda E de, J McAuliffe, D Kaiser, F Hayden and J Gwaltney Jr. The morbidity of respiratory illness in young children in a slum in northeast Brazil. Presented at the American Federation for Clinical Research, Washington, DC., February 1-3, 1989. *Clinical Res* 37:19A, 1989.
61. Hayden FG, W Soo and A Hay. Failure of rimantadine prophylaxis due to transmission of drug-resistant influenza A virus in families. Presented at the American Federation for Clinical Research, Washington, DC., April 30, 1989. *Clinical Res* 37:430A, 1989.
62. Hsia J, GL Simon, AL Goldstein, P Naylor, MB Sztein and FG Hayden. Immune activation during rhinovirus colds. Presented at the American Federation for Clinical Research, Washington, DC., April 30, 1989. *Clinical Res* 37:431A, 1989.
63. Arruda E, TE Mifflin, B Winther and FG Hayden. Detection of rhinovirus infection *in situ* hybridization. Presented at the Annual Meeting of the American Society for Microbiology, New Orleans, LA., May 14-18, 1989 [abst #T45].
64. Hayden FG. Clinical significance of rimantadine resistance in influenza A viruses. Presented at the Symposium on Antiviral Therapy of Influenza A Virus Infections. Carmel, California, August 24, 1989.
65. Hayden FG. Treatment of respiratory viral infections. Presented at the American Society for Microbiology Workshop on Antiviral Chemotherapy. Houston, Texas, September 17, 1989.
66. Hayden FG. Efficacy of Intranasal R 77975 for the prevention of experimentally Induced rhinovirus infection and illness. Presented at the Third International Conference on Antiviral Research, Brussels, Belgium, April 26, 1990 [abst #122].

Bibliography

67. Hayden FG. Prevention and treatment of influenza. Presented at 1990 ALA/ATS/IUATLD World Conference on Lung Health, Boston, Mass., May 24, 1990.
68. Arruda E, TE Mifflin, B Winther, FG Hayden, et al. Localization of rhinovirus replication with in situ hybridization. Presented at 1990 Annual Meeting of the American Society for Virology, Salt Lake City, Utah, July 11, 1990.
69. Hayden FG. Prevention and Treatment of Rhinovirus Infections. Presented at the Workshop on Antiviral Agents, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 21, 1990.
70. Hayden FG. Management of Influenza: Therapeutic Issues. Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 22, 1990.
71. Whitley R, C Liu, R Pollard, F Hayden, et al. Acyclovir versus vidarabine therapy of disseminated herpes zoster in the immunocompromised host. Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 21-24, 1990 [abst# 728].
72. Hayden F, R Belshe, R Clover, A Hay, and S Pyke. Therapeutic efficacy of rimantadine HCl and relationship to shedding of drug-resistant influenza A virus. Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 21-24, 1990 [abst# 1146].
73. Hayden F. Clinical importance of drug resistance in influenza viruses. Presented at the Fourth International Conference on Antiviral Research, New Orleans, Louisiana, April 21-26, 1991.
74. Last-Barney K, SD Marlin, C Cahill, R Jejer, D Fortugno-Erikson, M O'Neill, F Hayden, and VJ Merluzzi. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Presented at the Fourth International Conference on Antiviral Research, New Orleans, Louisiana, April 21-26, 1991. Antiviral Res 15 (suppl 1): 107, 1991 [abst # 119].
75. Sperber SJ, BV Smith, and FG Hayden. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. Presented at the Frontiers in Vaccine Research International Symposium at Hanasaari, Espoo, Finland, September 9-11, 1991.
76. Arruda E, C Crump, S Marlin, V Merluzzi, and F Hayden. Anti-rhinovirus activity of soluble intercellular adhesion molecule-1 in cell cultures and organ cultures of human respiratory epithelium. Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 29-October 2, 1991 [abst #771].
77. Hayden FG. Update on treatment of respiratory viral infections. Presented at the Third Triennial Symposium on New Directions in Antiviral Chemotherapy, San Francisco, California. November 14-16, 1991.
78. Turner RB and FG Hayden. Efficacy of oral WIN 54954 for the prophylaxis of experimental rhinovirus infection. Presented at the Fifth International Conference on Antiviral Research, Vancouver, Canada. March 8-13, 1992. Antiviral Res 17(suppl 1): 92, 1992 [abst #91].
79. Hayden FG. Antivirals in common cold. Presented at the First International Meeting on Upper Respiratory Tract Infections (FIURT), Malta. April 28, 1992.
80. Hayden FG. What are the problems with antiviral agents and what are the prospects for new agents? Presented at the SKB Anti-infective Conference: Controversies in Infectious Disease, Tucson, AZ, September 10-12, 1992.

Bibliography

81. Hayden F. Development of antiviral-resistant mutants during rimantadine therapy. Presented at the International Scientific Conference Options for the Control of Influenza II, Courchevel, France. September 26-October 2, 1992.
82. Hayden F. Drug resistance in respiratory viruses. Presented at the Symposium on Significance of Antiviral Resistance in Human Diseases for the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California. October 11-14, 1992.
83. Hayden F, J. Treanor, and J. Harris. Multi-dose oral LY217896 for prevention of experimental human influenza A virus infection and illness. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California. October 11-14, 1992 [abst #407].
84. Arruda E and Hayden FG. Detection of human rhinovirus RNA in nasal washes by polymerase chain reaction (PCR). Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California. October 11-14, 1992 [abst #1239].
85. Jernigan JA, FG Hayden, DHM Groschel, and BM Farr. Adenovirus type 8 epidemic keratoconjunctivitis (EKC) in an eye clinic: risk factors and control. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California. October 11-14, 1992 [abst #1411].
86. Skoner DP, WJ Doyle, F Hayden, CA Buchman, JT Seroky, and P Fireman. Otitis media (OM) as a manifestation of experimental influenza A virus infection. Presented at the Society of Pediatric Research, Washington, D.C. May 3-6, 1993 [abst #1083].
87. Hayden F, A Elkhateb, J DiGennario, and D Riker. Efficacy and safety of naproxen in the treatment of naturally occurring colds. Presented at the IX International Congress of Virology, Glasgow Scotland, August 12, 1993 [abst # W53-2].
88. Hayden F, A Elkhateb, G Hipskind, and D Woerner. Middle ear abnormalities during natural rhinovirus colds in adults. Presented at the IX International Congress of Virology, Glasgow, Scotland, August 12, 1993 [abst # P53-3].
89. Hayden FG. Respiratory viral infections in transplant patients. Presented at the North American Transplant Infectious Disease Symposium, Boston, MA, November 17-19, 1993.
90. Hayden F, B Rollins and L Madren. Anti-influenza virus activity of 4-guanidino-2, 4-dideoxy-2,3-dehydro-*N*-acetylneuraminic acid in vitro. Presented at Seventh International Conference on Antiviral Research, Charleston, SC, February 27- March 4, 1994. *Antiviral Res* 23(suppl 1):133, 1994 [abst #184].
91. Hayden FG. In vitro studies of 4-guanidino Neu5Ac2en: activity in human respiratory epithelium and potential for resistance development. Presented at the Sialidase Workshop, Rigi Kaltbad, Switzerland, April 18-19, 1994.
92. Hayden FG. New and emerging viral infections. Presented at the American College of Physicians Current Concepts of Clinical Infectious Diseases, Charlottesville, VA, April 13-15, 1994.
93. Hayden FG. The case for and against rimantadine and amantadine. Presented at AGS/AFAR Annual Meeting, Los Angeles, CA, May 19, 1994.
94. Arruda E, TR Boyle, B Winther, DC Pevear, MJ Gwaltney, Jr., and FG Hayden. Localization of human rhinovirus (HRV) replication in the upper respiratory tract of humans by *in situ* hybridization (ISH). Presented at the American Society for Virology 13th Annual Meeting, Madison, Wisconsin, July 9-13, 1994 [abst #W23-5].
95. Hayden F, M Lobo, J Esinhart, and B Hussey. Efficacy of 4-guanidino Neu5Ac2en in experimental

Bibliography

- human influenza A virus infection. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting, Orlando, FL, October 4-7, 1994 [abst #H35].
96. Blumberg EA, SC Brozena, PC Stutman, C Crumb, J Fitzpatrick, J Alpern, A Gash, and FG Hayden. Immunogenicity and efficacy of influenza vaccine in heart transplant recipients. Presented at the Infectious Diseases Society of American, Orlando, FL, October 7-9, 1994 [abst #218].
 97. Hayden FG. Nosocomial respiratory viral infections. Presented at the Eighteenth Annual Symposium for Clinicians on Hospital Infection Control, Charlottesville, VA, November 3-4, 1994.
 98. Hayden FG. Update on antiviral therapy of influenza and rhinovirus infections and other respiratory viral infections. Presented at the Fourth Triennial Symposium on New Directions in Antiviral Chemotherapy, San Francisco, CA, November 10-12, 1994.
 99. Hayden FG. Anti-influenza virus activity of the novel neuraminidase inhibitor 4-guanidino-Neu5Ac2en. Presented at the Second Annual Meeting on Antivirals: Genetic Approaches and Clinical Developments, Washington DC, November 17-18, 1994.
 100. Hayden FG. Evaluation of candidate antiviral compounds in experimental human influenza. Presented at the 28th Annual ASCEPT Meeting, Auckland, New Zealand, December 5-7, 1994.
 101. Hayden FG. Human studies of resistance in influenza virus. Presented at the Consensus Symposium on Antiviral Resistance, Hamilton, Bermuda, December 8-10, 1994.
 102. Hayden FG. Antiviral agents for respiratory viral infections. Presented at World Health Organization Meeting on the Progress in the Development and Use of Antiviral Drugs and Interferon, Geneva, March 13-15, 1995.
 103. Hayden FG, JJ Treanor, J Esinhart, CU Eason, EK Hussey. Twice daily intranasal GG167 for experimental influenza A. Presented at the Eighth International Conference on Antiviral Research, Sante Fe, New Mexico, April 23-28, 1995. *Antiviral Res* 26(3):A300, 1995 [abst #140].
 104. Hayden FG. Antiviral drug resistance. Presented at the 95th General Meeting American Society for Microbiology, Washington D.C., May 25, 1995.
 105. Fireman P, DP Skoner, WJ Doyle, J Seroky, F Hayden, JM Gwaltney. Effect of rhinovirus 39 (RV) and influenza virus (FLU) infections on the lower airways in allergic rhinitis (AR) and non-AR subjects. Presented at the 51st Annual Meeting of American Academy of Allergy and Immunology, February 24-March 1, 1995. *Allergy Clin Immunology* 95:300, 1995 [abst #994].
 106. Hayden FG. Combination antiviral therapy for respiratory virus infections. Presented at Consensus Symposium on Combined Antiviral Therapy, Lisbon, Portugal, July 1, 1995.
 107. Hayden FG. Amantadine and rimantadine resistance in influenza A viruses. Presented at the 19th International Congress on Chemotherapy, Montreal, Quebec, Canada, July 16-21, 1995, *Can J Infect Dis* 6:267C, 1995 [abst #0505].
 108. Hayden F, J Treanor, R Betts, J Esinhart, C Eason, E Hussey. Intranasal GG167 for prevention and treatment of experimental influenza. Presented at the Joint Meeting of the European Group for Rapid Viral Diagnosis and the European Society Against Viral Diseases, September 13, 1995, Prague, Czech Republic.
 109. Hussey E, F Hayden, C Grosse, C Eason, D Morris. Serum and urine GG167 concentrations in healthy subjects inoculated experimentally with influenza A virus. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-29, 1995 [abst #A132].

Bibliography

110. Hayden FG. New therapies for respiratory viral infections. Presented at the 33rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, September 17, 1995.
111. Hayden FG. Influenza virus infections. Presented at Emerging Disease: Update 1995, Lisbon, Portugal, October 10, 1995.
112. Rakes GP, E Arruda, JM Ingram, GE Hoover, FG Hayden, TAE Platts-Mills, PW Heymann. Human rhinovirus in wheezing children: relationship to serum IGE and nasal eosinophil cationic protein. Presented at American Academy of Allergy and Asthma, and Immunology. New York, NY, February 1995
Am J of Resp Crit Care Med 1995;151 [abst #362].
113. Rakes GP, Arruda E, Ingram JM, Hoover GE, Hayden FG, Platts-Mills TAE, Heymann PW. Assessment of viral pathogens and eosinophil cationic protein in nasal washes from wheezing infants and children. J Allerg Clin Immunol 1995;95 [abst #477].
114. Hayden FG. How do you diagnose this and is there really a new treatment for flu? Presented at Update '96, Whistler, British Columbia, February 3-6, 1996.
115. Hayden FG. Critical respiratory viral pathogens. Presented at the Society of Critical Care Medicine (SCCM), New Orleans, LA, February 5-9, 1996.
116. Hayden FG, Hussey EK, Eason CU. Efficacy of GG167 administered as intranasal sprays in healthy susceptible volunteers following influenza A and B challenge. Presented at the Third International Conference on Options for Control of Influenza, Cairns, Australia, May 4-9, 1996 [abst #S4-1, p 25]
117. Hayden FG, Rollins BR, Hirst HM, Hussey EK. GG167 susceptibility of influenza A viruses recovered after GG167 administration. Presented at the Third International Conference on Options for Control of Influenza. Cairns, Australia, May 4-9, 1996, [abst #W4-6, p36]
118. Hayden, FG. Viral infections of the upper and lower respiratory tract and sinusitis. Presented at Eighth Annual Course, Infectious Diseases '96, Washington, DC, May 17-19, 1996.
119. Hayden, FG. Influenza virus resistance to amantadine and rimantadine. Presented at Medical Virology Cub Satellite Symposium, Hamilton, Ontario, July 12, 1996.
120. Fritz, RS, Lobo MC, Alvord WG, Strober W, Straus SE and Hayden FG. Cytokine elaboration and symptom pathogenesis during acute influenza a virus infection. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 16-19, 1996. [abst #H46, p.171]
121. Rotbart HA, Brennan PJ, Fife KH, Romerero JR, Griffin JA, McKinley MA, Hayden FG. Enterovirus meningitis in adults. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 16-19, 1996. [abst #H41 p.170]
122. Hayden F, Osterhaus A, Treanor J, Aoki F, Keene O, and GG167 Study Group. Phase II studies of the therapeutic efficacy and safety of GG167 in uncomplicated influenza. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 16-19, 1996. [abst #H45 p.171]
123. Hayden, FG. Update on clinical studies with the novel neuraminidase inhibitor GG167. Presented at IBC 's International Industry Conference on Influenza and Other Respiratory Diseases, Washington, DC, September 26-27, 1996.
124. Hayden, FG. Clinical importance of amantadine resistance in influenza viruses. Presented at the 4th Annual Work Group Meeting on Improving the Performance of Influenza and Pneumococcal Vaccines in

Bibliography

- Adults, Institute of Aging and Immunology, Washington, DC, October 8-9, 1996.
125. Hayden, FG. Update on GG167. Presented at the 4th Annual Work Group Meeting on Improving the Performance of Influenza and Pneumococcal Vaccines in Adults, Institute of Aging and Immunology, Washington, DC, October 8-9, 1996.
 126. Hayden, FG. Update on treatment of influenza. Presented at the 7th Swiss Glaxo Wellcome Workshop Challenge in Virology, Saanen-Gstaad, Switzerland, January 10-12, 1997.
 127. Hayden, FG. Influenza virus neuraminidase inhibitors. Presented at the Seventh International Antiviral Symposium, Sydney, Australia, February 17-19, 1997. [abst #14, p.23]
 128. Hayden, FG. Respiratory viruses and new compounds. Presented at Virology: A New Perspective, Canberra, Australia, February 21, 1997.
 129. Hayden, FG. Rhinoviruses, ICAM-1 and respiratory tract. Presented at the 36th Annual Swineford Allergy Conference, Charlottesville, VA, April 18-19, 1997.
 130. Arruda E, Pitkaranta A, Witek TJ, Doyle CA, Hayden FG. Etiology and clinical course of common colds during autumn months. Presented at American Thoracic Society, San Francisco, CA, May 18, 1997.
 131. Hayden, FG. Treatment of non-HIV viral infections. Presented at the Second Conference on New and Reemerging Infectious Diseases, Atlanta, GA, June 8, 1997.
 132. Hayden, FG. Antivirals for ARI. Presented at the International Conference on Acute Respiratory Infections, Canberra, Australia, July 7-10, 1997.
 133. Hayden, FG. Influenza: advances in vaccines and antivirals, including inhaled zanamivir treatment. Presented at the Haartman Seminar, Haartman Institute, Helsinki, Finland, September 4, 1997.
 134. Hayden, FG. Respiratory viruses. Presented at the III International Consensus Symposium on Novel Developments in Antiviral Therapy, Istanbul, Turkey, September 7-9, 1997.
 135. Hayden, FG. Prospects of anti-viral interventions in the airways. Presented at the Annual Congress of the European Respiratory Society, Berlin, Germany, September 24, 1997.
 136. Pitkaranta A, Arruda E, Virolainen A, Jero J, and Hayden FG. Detection of rhinovirus, respiratory syncytial virus and coronavirus RNA in children with acute otitis media. Presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28 - October 1, 1997. [abst #H-83, p. 228]
 137. Turner RB, Wecker MT, Pohl G, Witek TJ, Marlin S, McNally E and Hayden, FG. Efficacy of soluble ICAM-1 (sICAM) for prevention of rhinovirus infection and illness. Presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28 - October 1, 1997. [abst #H-85, p. 229]
 138. Hayden FG, Lobo M, Treanor JJ, Miller M, Mills RG. Efficacy and tolerability of oral GS4104 for early treatment of experimental influenza in humans. Presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28 - October 1, 1997. [abst #LB-26, p14]
 139. Hayden FG. Antiviral resistance in respiratory viruses. Presented in Symposium on Treatment - Resistant Viruses at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 26, 1997.
 140. Hayden FG. Update on neuraminidase inhibitors. Presented at the 5th Annual Work Group Meeting on

Bibliography

- Improving the Performance of Influenza and Pneumococcal Vaccines in Adults, Institute of Aging and Immunology, Washington, DC, October 7-8, 1997.
141. Hayden FG. Influenza - New strategies for treatment. Presented at the Fifth Triennial Symposium, New Directions in Antiviral Chemotherapy, San Francisco, CA, November 13-15, 1997.
 142. Hayden, FG. Rhinovirus: New approaches. Presented at the Fifth Triennial Symposium, New Directions in Antiviral Chemotherapy, San Francisco, CA, November 13-15, 1997.
 143. Hayden, FG. What's new with flu? and Common cold controversies. Presented at the Update '98, Whistler, B.C., Canada, February 7-10, 1998
 144. Hayden, FG. What 's new in treatment of herpes infections. Presented at the Current Concepts of Clinical Infectious Disease, Charlottesville, VA April 15-17, 1998.
 145. Hayden, FG. Influenza neuraminidase inhibitors: A review. Presented at the 1998 Harold C. Neu Infectious Diseases Conference, Seattle, WA, April 30- May 3, 1998.
 146. Hayden, FG. Newer treatments and preventive strategies for influenza. Presented at APIC 98 - The 25th Annual Educational Conference & International Meeting, San Diego, CA, May 10-14, 1998.
 147. Hayden, FG. Influenza neuraminidase inhibitors: A review. Presented at the Harold C. Neu Infectious Diseases Conference, Seattle, WA, April 30-May 2, 1998.
 148. Hayden, FG. Influenza and Rhinoviruses. Presented at the Tenth International Symposium on Infections in the Immunocompromised Host, Davos, Switzerland, June 21-24, 1998.
 149. Hayden FG. Clinical efficacy of antiviral agents: Influenza neuraminidase inhibitors. Presented at the Groupe d' Etude et d' Information sur la Grippe XIIth European Meeting on Influenza and its Prevention, September 17-18, 1998 Biarritz, France.
 150. Hayden FG. Antivirals for influenza neuraminidase inhibition: Focus on oral GS4104. Presented in Symposium on Meeting the Challenge of Influenza at the European Respiratory Society Annual Congress, September 22, 1998, Geneva, Switzerland.
 151. Hayden FG, Fritz RS, Lobo M, Kinnersley N, Mills RG, and Straus SE. Effects of the oral neuraminidase inhibitor GS410 on cytokine response during experimental human influenza A virus infection. Presented at the European Respiratory Society Annual Congress, September 2, 1998, Geneva Switzerland. European Respiratory Journal 263S:abst #1799, 1998.
 152. Hayden, FG. Influenza Neuraminidase Inhibitors. Presented in Symposium on Advances in Treatment and Control of Influenza at the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27, 1998.
 153. Fritz RS, Hayden FG, Calfee DP, Cass LMR, Peng AW, Alvord WG, and Straus SE. Cytokine and chemokine responses during experimental influenza A infection: Effect of intravenous zanamivir. Program and abstracts from the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 26, 1998. [abst # H-57, p 51]
 154. Calfee DP, Peng AW, Cass LMR, Lobo M, and Hayden FG. Protective efficacy of intravenous zanamivir in experimental human influenza. Program and abstracts from the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998. [abst #H-58, p 52]
 155. Calfee DP, Peng AW, Hussey EK, Lobo M. and Hayden FG. Protective efficacy of reduced-frequency

Bibliography

- dosing of intranasal zanamivir in experimental human influenza. Program and abstracts from the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998. [abst #H-68, p 334]
156. Treanor JJ, Vrooman PS, Hayden FG, Kinnersley N, Ward P, and Mills RG on behalf of the US oral neuraminidase inhibitor study group. Efficacy of oral GS4104 in treating acute influenza. Program and abstracts from the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 25, 1998. [abst #LB-4, p 17]
157. Hayden FG, Atmar R, Schilling M, Johson C, Poretz D, Parr D, Huson L, Ward P, and Mills R. Safety and efficacy of oral GS4104 in longterm prophylaxis of natural influenza. Program and abstracts from the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 26, 1998. [abst #LB-6, p18].
163. Hayden FG. When should we treat respiratory virus infections? Presented in Symposium on New Strategies In Managing Viral Diseases at the 5th Conference of the Federation of Infection Societies, Manchester, UK, November 25-27, 1998.
164. Hayden FG. When should we treat respiratory virus infections? Presented at the 5th Conference of the Federation of Infection Societies, Manchester, UK, November 25-27, 1998. [abst #1.4, p18].
165. Hayden FG. Antiviral treatment of respiratory virus infections. Presented at the European Society for Clinical Virology Winter Meeting, Rotterdam, The Netherlands, January 7-9, 1999.
166. Hayden FG. Antiviral treatment of common colds and influenza. Presented at the Annual Congress of Finnish Medical Society, Helsinki, Finland, January 3-7, 1999.
167. Hayden, FG. New developments in antivirals and vaccines against influenza. Presented at Challenge in Virology, the 9th Swiss Glaxo Wellcome Workshop, Saanen, Switzerland, January 15-17, 1999.
168. Zambrano JC, Carper HT, Hayden, FG et al. Inflammatory airway responses to experimental rhinovirus-16 infection in asthma subjects: Exhaled nitric oxide (NO), soluble ICAM-1, nasal eosinophil cationic protein (ECP). Presented at 1999 American Academy of Allergy and American Thoracic Society International Conference, April 23-28, 1999, San Diego, CA
169. Zambrano JC, Carper HT, Hayden, FG et al. Experimental rhinovirus-16 infection in asthma patients: Exhaled nitric oxide (NO)and eosinophil cationic protein (ECP). Presented at 1999 American Academy of Allergy and American Thoracic Society International Conference, April 23-28, 1999, San Diego, CA
170. Hayden, FG. Advances in influenza management: focus on neuraminidase inhibitors and intranasal vaccine. Presented at the 9th European Congress of Clinical Microbiology and Infectious Diseases, Berlin Germany, March 21-24, 1999.
171. Hayden, FG. Influenza neuraminidase inhibitors. Presented at the 143rd Meeting of the Society for General Microbiology, Edinburgh, Scotland, April 12, 1999.
172. Hayden, FG. Influenza neuraminidase inhibitors. Presented at the 15th Annual Clinical Virology Symposium and Pan American Society for Clinical Virology, Clearwater Beach, FL, May 9-12, 1999.
173. Hayden, FG. Influenza, the continually re-emerging plague. Presented at the 13th Annual Biologic Basis of Pediatric Practice Symposium, Brian Head, Utah, July 9-11, 1999.
174. Hayden, FG. The genetics of influenza; Implication for vaccine development. Presented at the 13th Annual Biologic Basis of Pediatric Practice Symposium, Brian Head, Utah, July 9-11, 1999.

Bibliography

175. Hayden, FG. Antiviral therapy and chemoprophylaxis for influenza. Presented at the 21st International Congress of Chemotherapy, Birmingham, UK, July 4-7, 1999. *The Journal of Antimicrobial Chemotherapy*. 44 (Suppl A):13, 1999 [abst #15-67]
176. Hayden FG, Gubareva L, Klein T, Elliott MJ, Hammond J, Ossi M, Sharp S, Monto AS. Inhaled zanamivir for preventing transmission of influenza in families. 39th ICAAC Final Program, Abstracts and Exhibits Addendum. San Francisco, CA, September 26-29, 1999
177. Hayden, FG. Influenza: Virulence factors, therapeutic strategies. Presented at the 2nd Bernese Infectious Diseases Symposium. Berne, Switzerland. October 21, 1999.
178. Hayden, FG. Status of pleconaril and 3C protease inhibitors for rhinovirus. Presented at the II International Symposium on Influenza and Other Respiratory Viruses. Grand Cayman, Cayman Islands, December 10-12, 1999
179. Gubareva LV, Schallon D, and Hayden FG. Activity of the neuraminidase inhibitor RWJ-270201 (BCX-1812) against influenza A and B viruses in the neuraminidase inhibition assays. Presented at the II International Symposium on Influenza and Other Respiratory Viruses. Grand Cayman, Cayman Islands, December 10-12, 1999.
180. Hayden, FG. Influenza – Epidemiology in clinical practice. Presented at the Influenza Conference, Global Challenges – New Treatments. Salt Lake City, UT, January 14, 2000.
181. Hayden, FG. Antivirals for influenza. Presented at the Stockholm Virology Meeting, Stockholm, Sweden, February 3-5, 2000.
182. Hayden FG. Influenza Treatments: Role for neuraminidase inhibitors. Presented at Update 2000, Whistler, British Columbia, Canada, February 7, 2000.
183. Hayden FG. The common cold. Presented at Update 2000, Whistler, British Columbia, Canada, February 7, 2000.
184. Hayden, FG. Antiviral agents for influenza. Presented at the Workshop on Treatment of Influenza “New Perspectives”. Utrecht, Netherlands, February 16, 2000.
185. Hayden, FG. Advances in antiviral management of rhinovirus and influenza infections. Presented at the International Symposium on Otitis Media. Annecy, France, February 13-16, 2000.
186. Hayden, FG. Influenza: Advances in Prevention and Treatment. Presented at the Stanford University/Palo Alto Medical Foundation 26th Winter Course in Infectious Diseases. Vale, Colorado, February 20-25, 2000.
187. Hayden, FG. Rhinovirus: New Insights on Epidemiology, Pathogenesis, and Management. Presented at the Stanford University/Palo Alto Medical Foundation 26th Winter Course in Infectious Diseases. Vale, Colorado, February 20-25, 2000.
188. Hayden, FG. Preventing influenza in acute care settings. Presented at the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections, Atlanta, Georgia, March 8, 2000.
189. Hayden, FG. Safety and efficacy of an oral neuraminidase inhibitor RWJ-270201 in treating experimental influenza A in healthy adult volunteers. Presented at the 9th International Congress on Infectious Diseases, Buenos Aires, Argentina, April 10-13, 2000 [abst #80.018, p 184]
190. Hayden, FG. Current treatment of influenza. Presented at the 9th International Congress on Infectious Diseases, Buenos Aires, Argentina, April 10-13, 2000 [abst #57.003, p137]

Bibliography

191. Hayden, FG. Clinical studies for influenza neuraminidase inhibitors. Presented at the 13th International Conference on Antiviral Research, Baltimore, MD, April 16-21, 2000. Antiviral Research 46:A26, 2000.
192. Gubareva LV, Tai CY, Mendel DB, Ives J, Carr J, Roberts NA, and Hayden FG. Oseltamivir treatment of experimental influenza A/Texas/36/91 (H1N1) virus infection in humans: selection of a novel neuraminidase variant. Presented at the 13th International Conference on Antiviral Research, Baltimore, MD, April 16-21, 2000. Antiviral Research 46:A59, 2000 [abst #78].
193. Carr J, Ives J, Roberts N, Kelly L, Lambkin R, Oxford J, Tai CY, Mendel D, and Hayden F. Virological assessment *in vitro* and *in vivo* of an influenza H1N1 virus with a H274Y mutation in the neuraminidase gene. Presented at the 13th International Conference on Antiviral Research, Baltimore, MD, April 16-21, 2000. Antiviral Research 46:A59, 2000 [abst #79].
194. Gubareva LV, Webster RG, and Hayden FG. Cross resistance of influenza virus mutants to NA inhibitors: Zanamivir, GS4071, and RWJ-270201. Presented at the 13th International Conference on Antiviral Research, Baltimore, MD, April 16-21, 2000. Antiviral Research 46:A54, 2000 [abst #63].
195. Hayden FG, Ward P, and Roberts N. Oral oseltamivir in experimental human influenza B virus infection: Lack of resistance emergence. Presented at the 13th International Conference on Antiviral Research, Baltimore, MD, April 16-21, 2000. Antiviral Research 46:A54, 2000 [abst #65].
196. Hayden FG, Treanor J, Qu R, and Fowler CL. Efficacy and safety of the oral neuraminidase inhibitor RWJ-270201 in treating experimental human influenza A infections. Presented at the 3rd European Congress of Chemotherapy, Madrid Spain, May 7-10, 2000. Spanish Journal of Chemotherapy 13:22. [abst M188].
197. Hayden FG. New antiviral strategies for management of influenza. Presented at the 10th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, Sweden, May 28-31, 2000. Clinical Microbiology and Infection 6 (Suppl 1):250, 2000. [abst #MoS2].
198. Reisinger K, Hayden FG, Whitley R, Dutkowski R, Ipe D, Mills R, Ward P. Oral oseltamivir is effective and safe in the treatment of children with acute influenza. Presented at the 10th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, Sweden, May 28-31, 2000. Clinical Microbiology and Infection 6 (Suppl 1):250,140, 2000. [abst #WeP257].
199. Hayden FG. Neuraminidase inhibitors for influenza. Pro-and-con debate at the 10th European Congress of clinical Microbiology and Infectious Diseases, Stockholm, Sweden, May 28-31, 2000.
200. Hayden, FG. New drugs to treat respiratory viral infections. Presented at the New and Reemerging Infectious Diseases: A Clinical Course, Atlanta Georgia, June 3-5, 2000.
201. Drusano GL, Treanor JJ, Fowler CL, Preston SL, Qu R, Natarajan J, Iyer G and Hayden FG. Time to viral clearance after experimental infection with influenza B is related to the cumulative area under the curve of RWJ-270201. Presented at the 38th Annual Meeting of the Infectious Disease Society of America, September 7-10, 2000 New Orleans, LA. [abst #610, p 146].
202. Winther B, Hendley JO, Joyner P, and Hayden FG. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for diagnosis of human rhinovirus (HRV) infections in children. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. [abst #189, p 262].
203. Kaiser L, Fritz RS, Straus SE, Gubareva L, and Hayden FG. Symptom pathogenesis during acute influenza – IL-6 and other cytokine responses. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. [abst #178, p 260].

Bibliography

204. Boeckh M, Hayden F, Corey L, and Kaiser L. Detection of rhinovirus RNA in bronchoalveolar lavage in hematopoietic stem cell transplant recipients with pneumonia. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. [abst #190, p 262].
205. Hayden F, Treanor J, Qu R, and Fowler C. Safety and efficacy of an oral neuraminidase inhibitor RWJ-270201 in treating experimental influenza A and B in healthy adult volunteers. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. [abst #1156, p 270].
206. Hayden FG, Kim K, Coats T, Blatter M, and Drehobl M. Pleconaril treatment shortens duration of picornaviral upper respiratory illness in adults. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. [abst #1161, p 272].
207. Winther B, Hayden FG, Whitley R, Reisinger K, Dutkowski R, Ipe D, Ward P. and Mills R. Oral oseltamivir reduces the risk of developing acute otitis media following influenza infection in children. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. [abst #977, p 480]
208. Hayden FG. Influenza neuraminidase inhibitors: Clinical aspects. Presented at Options for the Control of Influenza IV, September 23-28, 2000, Crete, Greece. [abst #27, p 8].
209. Hayden FG, Reisinger KS, Whitley R, Dutkowski R, Ipe D, Mills R, and Ward P. Oral oseltamivir is effective and safe in children for the treatment of acute influenza A and B. Presented at Options for the Control of Influenza IV, September 23-28, 2000, Crete, Greece. [abst #W22-1, p 20]
210. Nedyalkova MS, Hayden FG, Webster RG, and Gubareva LV. Accumulation of subgenomic RNAs of segment 6 of influenza A but not B viruses passaged in the presence of neuraminidase inhibitors. Presented at Options for the Control of Influenza IV, September 23-28, 2000, Crete, Greece. [abst #W23-4, p 24, 26].
211. Hayden FG. Update on Influenza. Presented at the 4th Annual Virginia Pulmonary Conference and Research Symposium, October 7, 2000, Richmond, VA.
212. Hayden FG. Influenza Neuraminidase Inhibitors: Clinical Aspects. Presented at Vaccines 2000 Institute for Advanced Studies in Aging and Geriatric Medicine, October 23, 2000, Washington, DC.
213. Hayden FG. Advances in influenza management. Presented at the 78th Annual Fall Conference, Kansas City Southwest Clinical Society, October 27, 2000, Kansas City, MO.
214. Hayden FG. Prevention and Treatment, Presented at the American College of Allergy, Asthma & Immunology Annual Meeting, November 2, 2000, Seattle, WA.
215. Hayden FG. Influenza neuraminidase inhibitors: Clinical aspects. Presented at the Eighth International Antiviral Symposium and Workshop, November 19, 2000, Kogoshima, Japan. [abst #S7]
216. Hayden FG. Influenza antivirals in perspective. Presented at the Third International meeting on the Therapy of Infections, December 5, 2000, Florence, Italy.
217. Hayden FG. Recent advances in the prevention and treatment of influenza. Presented at the 11th Swiss Glaxo Wellcome Workshop: Challenge in Virology, Saanen-Gstaad, Switzerland, January 12, 2001.
218. Hayden FG. What's new with influenza? Presented at the 27th Winter Course in Infectious Diseases, Snowmass, CO, February 26, 2001.

Bibliography

219. Hayden, FG. Viral Pneumonias: A primer. Presented at the 27th Winter Course in Infectious Diseases, Snomass, CO, March 2, 2001.
220. Hayden FG. Influenza management: advances and unmet needs. Presented at the Antiviral Drug Discovery and Development Summit, Princeton, NJ, March 28, 2001.
221. Hayden FG. Influenza antivirals in perspective. Presented at the 41st Annual meeting of the Japanese Respiratory Society, April, 2001, Tokyo, Japan. *Journal of the Japanese Respiratory Society* 39 (#3 Suppl-2):97,2001 [abst #ES 5-3].
222. Hayden FG. In vitro anti-rhinovirus spectrum and potency of BTA188, a novel, oral picornavirus capsid binder. Presented at the 14th International Conference on Antiviral Research, Seattle, WA, April 8-12, 2001. *Antiviral Research* 50:A75, 2001. [abst #127]
223. Hayden FG. Influenza antivirals in perspective. Presented at the Royal Society Discussion Meeting on the origin and control of pandemic influenza, London, April 26, 2001.
224. Hayden FG. Influenza diagnostics. Presented at the 7th Conference of the International Society of Travel Medicine, Innesbruck, Austria, May 27-31, 2001 [abst # PL04.03]
225. Hayden FG. Anti-influenza chemoprophylaxis and treatment for travelers. Presented at the 7th conference of the International Society of Travel Medicine, Innesbruck, Austria, May 27-31, 2001 [abst # SY11.03]
226. Hayden, FG. Treating and preventing influenza with neuraminidase inhibitors. *International Journal of Antimicrobial Agents* 17(Suppl. 1) S56, 2001. [abst #S20.04]
227. Kaiser L, Ward P, Mahoney P, Hayden FG. Oral oseltamivir reduced complications and hospitalizations resulting from influenza infection: a meta-analysis. *International Journal of Antimicrobial Agents* 17(Suppl. 1) S117, 2001. [abst #P24.204]
228. Hayden FG. New drugs to treat viral respiratory infections. Presented at the New and Reemerging Infectious Diseases: A Clinical Course, Atlanta, GA, June 8-10, 2001
229. Hayden FG. Influenza. Presented at the 5th Congress of Infectious Diseases, Cartagena De Indias, Colombia, June 13-15, 2001.
230. Gomes R, Cintra OAL, Gubareva L, Hayden FG, Arruda E. Development of a duplex RT-PCR assay for the detection of influenza virus in clinical samples and comparison with quick-vue and viral isolation in shell vial. Presented at the American Society for Virology 20th Annual Meeting, Madison, Wisconsin, July 21-25, 2001. [abst #P5-5]
231. Macedo IS, Borges EB, Silva ML, Winther B, Arruda LK, Camara AA, Hayden FG, Arruda E. Development and application of an assay based on RT-PCR and hybridization for the detection of human coronaviruses OC43 and 229E. Presented at the American Society for Virology 20th Annual Meeting, Madison, Wisconsin, July 21-25, 2001. [abst #P5-6]
232. Hayden FG. New non-HIV antivirals. Presented at the 39th Annual meeting of the Infectious Diseases Society of America, San Francisco, CA, October 25-28, 2001. [abst #S77]
233. Hayden FG, Kim K, Hudson S and Villano A. Pleconaril treatment provides early reduction of symptom severity in viral respiratory infection (VRI) due to picornaviruses. Presented at the 39th Annual meeting of the Infectious Diseases Society of America, San Francisco, CA, October 25-28, 2001. [abst #414]